Introduction {#s1}
============

Monogenic and other genetic defects of the immune system, now collectively grouped as primary immunodeficiencies and immune dysregulatory disorders (PIDDs) affect various components of the immune system with susceptibility to infections, but also to autoimmunity, malignancies, and other manifestations of immune dysregulation ([@B7]--[@B9]). The number of genetically defined PIDDs is increasing with the current tally at well over 300 genes ([@B10]), and several of these are associated with an increased predisposition to developing neoplastic disease ([@B11]). Early studies have suggested a variable prevalence of malignancies in PIDDs with approximately 25% affected with cancer at the higher end of the spectrum ([@B2]). A recent large study spanning 12 years for patients enrolled in a national registry (USIDNET) revealed an age-adjusted cancer risk, as well as a gender-associated cancer risk with male patients predominating in this cohort ([@B12]). The largest proportion of risk was conferred by susceptibility to hematopoietic malignancies rather than solid tumors, in particular lymphoma. Herein, we describe a targeted literature review on the associations of B and T cell lymphomas with PIDDs, particularly with regard to specific immune defects. We will also reflect on current state of knowledge as regards to pathogenesis and management of lymphoid neoplasias in PIDDs.

Methods and Results {#s2}
===================

In these sections, we describe the strategy to identify relevant citations gathered for this review and a summary of the results. A comprehensive search of the MEDLINE database was initially conducted from its inception to October 17th, 2018. The search was updated on February 1st, 2019. Controlled vocabulary supplemented with keywords (which included lymphoma) was used to search for individual primary immunodeficiencies as per the IUIS 2017 classification. Search results and study selection are outlined in [Figure 1](#F1){ref-type="fig"}. Number of cases and type (B, T or unspecified) are shown in [Figure 2](#F2){ref-type="fig"}. The cases of B cell lymphomas, T cell lymphomas and unspecified lymphomas in PIDDs are summarized in [Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"} respectively.

![PRISMA flow diagram: The PRIMSA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram details our search and selection process applied during the overview.](fimmu-10-00777-g0001){#F1}

![Lymphoma distribution according to IUIS classification.](fimmu-10-00777-g0002){#F2}

###### 

Summary of B cell lymphomas in PIDDs.

  **PID**                                                                 **References**     ***N***   **Proposed mechanism**                   **Cancer**                                     **Specific mutations**                                                                                                    **Age/sex**                               **Manifestation/course**                                                                                                                                                                  **Treatment**                                                                                            **Outcome**
  ----------------------------------------------------------------------- ------------------ --------- ---------------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  **IMMUNODEFICIENCIES AFFECTING CELLULAR AND HUMORAL IMMUNITY**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Coronin 1a deficiency[^\*^](#TN1){ref-type="table-fn"}                  ([@B13])           2         EBV associated                           Pt1: DLBCL                                     Coronin-1a mutation: V134M/V134M                                                                                          1/M                                       Left orbit mass                                                                                                                                                                           Chemotherapy                                                                                             F/U at 11.5 y = CR
                                                                                                                                                Pt2: DLBCL                                     Coronin-1a mutation: V134M/V134M                                                                                          0.6/F                                     Cervicothoracoabdominal LN and cerebral lesion                                                                                                                                            Chemotherapy                                                                                             Died during induction therapy at 8.5 m of age
  DNA Ligase IV mutation[^\*^](#TN1){ref-type="table-fn"}                 ([@B14])           1         EBV associated                           DLBCL                                          LigIV gene: M249V substitution and a 5 nucleotide del from 1,270--1,274                                                   14/F                                      Progressive gingival swelling and high fever                                                                                                                                              Vincristine, cyclophosphamide, and prednisolone                                                          Died of respiratory aspergillosis
  Artemis-SCID[^\*^](#TN1){ref-type="table-fn"}                           ([@B15])           1         DNA repair defect                        BCL                                            Hypomorphic mutations of the Artemis gene                                                                                 5/F                                       Liver, lung, LN, skeletal muscle involvement                                                                                                                                              Rituximab                                                                                                Died of lymphoma
  RAG 1 mutation[^\*^](#TN1){ref-type="table-fn"}                         ([@B16])           1         NR                                       DLBCL                                          RAG1 gene: Allele 1 R314W[^\*^](#TN1){ref-type="table-fn"} Allele 2 R507W/R737H                                           2/F                                       Tumor of right tonsil                                                                                                                                                                     Rituximab, HSCT                                                                                          CR
  DNA Ligase IV mutation[^\*^](#TN1){ref-type="table-fn"}                 ([@B17])           1         DNA repair defect EBV associated         DLBCL                                          Compound heterozygous for a null allele and a hypomorphic mutation in DNA LigIV                                           2/F                                       High fever, cervical LN, hepatomegaly, necrotizing mucositis.                                                                                                                             Chemotherapy                                                                                             Pt. died of aspergillosis
  ZAP70 deficiency[^\*^](#TN1){ref-type="table-fn"}                       ([@B18])           1         EBV associated                           DLBCL                                          Zap70 Gene: c.836_837 delAT                                                                                               1/F                                       Generalized lymphadenopathy                                                                                                                                                               Vincristine, cyclophosphamide methylprednisolone                                                         Died of DIC, multiorgan failure
  ADA deficiency[^\*^](#TN1){ref-type="table-fn"}                         ([@B19])           1         EBV associated                           BCL                                            NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       Dead 1 week later
  ADA deficiency                                                          ([@B20])           1         EBV associated (suspected)               Immunoblastic plasmacytoid                     NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       Died at 4 y
  ADA deficiency                                                          ([@B21])           1         NS                                       DLBCL                                          A83D; Exon5 splice donor site c.573 + 1G\>A                                                                               10/M                                      6-week history of head- ache, eye deviation, and weakness.                                                                                                                                COP + APO + 6-MP; MTX                                                                                    Died after 5 m
  ADA deficiency                                                          ([@B22])           1         Immune dysregulation                     BL                                             Homozygous Q3X                                                                                                            14/F                                      Right hip pain and limping                                                                                                                                                                Chemotherapy                                                                                             CR 20 m later
  ADA deficiency                                                          ([@B23])           1         Immune dysregulation                     DLBCL                                          Homozygous W272X (c.815G \> A)                                                                                            3/F                                       Respiratory complaints and symptoms                                                                                                                                                       BFM 2004 protocol                                                                                        Died of septic shock and intracranial hemorrhage after starting treatment
  ADA deficiency[^\*^](#TN1){ref-type="table-fn"}                         ([@B24])           1         EBV associated                           Plasmablastic                                  Homozygous 462delG                                                                                                        18/F                                      Persistent fever, multiple lymphadenopathies and bilateral periorbital edema                                                                                                              Rituximab; APO; and cyclophosphamide + dexamethasone                                                     Patient died of a hemorrhagic alveolitis, 12 days after starting chemotherapy
  **COMBINED IMMUNODEFICIENCIES WITH ASSOCIATED OR SYNDROMIC FEATURES**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Ataxia Telangiectasia[^\*^](#TN1){ref-type="table-fn"}                  ([@B25])           12        NS                                       HL                                             NS                                                                                                                        10/8M, 4F                                 NR                                                                                                                                                                                        NS                                                                                                       10 pts died
                                                                                             38        NS                                       NHL                                            NS                                                                                                                        9/22M, 16F                                NR                                                                                                                                                                                        NS                                                                                                       28 pts died
  Ataxia Telangiectasia[^\*^](#TN1){ref-type="table-fn"}                  ([@B26])           1         DNA repair defect                        MZL                                            NS                                                                                                                        16/M                                      Chronic lymphadenitis, LN at left jaw, Cervical, celiac, para-aortic                                                                                                                      Rituximab                                                                                                CR
  Ataxia Telangiectasia[^\*^](#TN1){ref-type="table-fn"}                  ([@B27])           1         DNA repair defect                        HL                                             NR                                                                                                                        14/M                                      Cervical, axillary and mediastinal LN                                                                                                                                                     COPP                                                                                                     CR
  Ataxia Telangiectasia[^\*^](#TN1){ref-type="table-fn"}                  ([@B28])           1         EBV associated                           NHL                                            ATM gene (exon 39 and c.6095G4A)                                                                                          13/M                                      Waldeyer\'s ring, intrapulmonary, abd., tonsillar, cervical LN                                                                                                                            Rituximab, doxorubicin, dexamethasone, cytarabine, cyclophosphamide, etoposide, vincristine, HSCT        No recurrence on 3 y FU
  Wiskott Aldrich[^\*^](#TN1){ref-type="table-fn"}                        ([@B29])           1         EBV associated DNA repair defect         DLBCL                                          NR                                                                                                                        14/M                                      Cervical adenitis, neurological symptoms                                                                                                                                                  Rituximab                                                                                                Died
  Wiskott Aldrich[^\*^](#TN1){ref-type="table-fn"}                        ([@B30])           1         NS                                       BL                                             WASP gene missense mutation (105 C \> T) in exon 1                                                                        12/M                                      Recurrent colicky abd. pain and bloody stools                                                                                                                                             Rituximab, CHOP                                                                                          CR
  Wiskott Aldrich[^\*^](#TN1){ref-type="table-fn"}                        ([@B31])           1         EBV associated                           DLBCL                                          NS                                                                                                                        15/M                                      Progressive respiratory distress, night sweats                                                                                                                                            Cyclophosphamide, prednisone, radiotherapy, laser surgery                                                Died of lung infection
  Wiskott Aldrich[^\*^](#TN1){ref-type="table-fn"}                        ([@B32])           1         EBV associated                           HL                                             NS                                                                                                                        1                                         Pulmonary hilar LN                                                                                                                                                                        ABVD                                                                                                     CR for more than 4 y
  Wiskott Aldrich[^\*^](#TN1){ref-type="table-fn"}                        ([@B33])           1         EBV associated                           NHL                                            NR                                                                                                                        20/M                                      Lymphadenopathy, CNS, gastric wall, pulmonary lesions                                                                                                                                     Acyclovir, adenosine arabinoside                                                                         Died of sepsis
  Wiskott Aldrich[^\*^](#TN1){ref-type="table-fn"}                        ([@B34])           1         EBV associated                           IL                                             NS                                                                                                                        13/M                                      Rectosigmoid tumor                                                                                                                                                                        Chemotherapy, excision, L-asparaginase therapy                                                           Died of colon perforation
  DiGeorge Syndrome[^\*^](#TN1){ref-type="table-fn"}                      ([@B35])           1         EBV associated                           INHL                                           NS                                                                                                                        10m/F                                     Hemiparesis due to cerebral mass, mediastinal LN                                                                                                                                          Untreated                                                                                                Died
  Cartilage hair dysplasia[^\*^](#TN1){ref-type="table-fn"}               Unpublished        1         EBV associated                           DLBCL                                          RMRP gene                                                                                                                 51/M                                      Incidental lung nodule                                                                                                                                                                    R-CHOP                                                                                                   CR
  Cartilage hair dysplasia[^\*^](#TN1){ref-type="table-fn"}               Unpublished        1         EBV associated                           MZL                                            RMRP gene                                                                                                                 47/M                                      Fever, night sweats, lymphadenopathy                                                                                                                                                      Rituximab                                                                                                Under treatment with Rituximab for recurrence
  Cartilage hair dysplasia                                                ([@B36])           10        NS                                       Pt1: HL                                        70A \> G/70A \> G                                                                                                         20/M                                      NR                                                                                                                                                                                        NR                                                                                                       Died in 1 m
                                                                                                                                                Pt2: NHL                                       70A \> G/262G \> T                                                                                                        40/M                                      NR                                                                                                                                                                                        NR                                                                                                       Died same m.
                                                                                                                                                Pt3: NHL                                       dupTACTCTGTGA at 13/70A \> G                                                                                              45/F                                      NR                                                                                                                                                                                        NR                                                                                                       Died in 3 m
                                                                                                                                                Pt4: NHL                                       70A \> G/70A \> G                                                                                                         46/F                                      NR                                                                                                                                                                                        NR                                                                                                       Died in 6 m
                                                                                                                                                Pt5: NHL                                       Not tested                                                                                                                22/F                                      NR                                                                                                                                                                                        NR                                                                                                       Died in 2 m
                                                                                                                                                Pt6: NHL                                       70A \> G/70A \> G                                                                                                         6/F                                       NR                                                                                                                                                                                        NR                                                                                                       Died in 9 m
                                                                                                                                                Pt7: NHL                                       Not tested                                                                                                                21/M                                      NR                                                                                                                                                                                        NR                                                                                                       Died in 1 m
                                                                                                                                                Pt8: NHL                                       Not tested                                                                                                                26/M                                      NR                                                                                                                                                                                        NR                                                                                                       Alive 4.5 y
                                                                                                                                                Pt9: NHL                                       70A \> G/70A \> G                                                                                                         32/M                                      NR                                                                                                                                                                                        NR                                                                                                       Alive 11 y
                                                                                                                                                Pt10: NHL                                      70A \> G/70A \> G                                                                                                         33/F                                      NR                                                                                                                                                                                        NR                                                                                                       Alive 4.5 y
  NBS                                                                     ([@B37])           8         NS                                       Pt1: DLBCL                                     Homozygous 657del5                                                                                                        10/M                                      DLBCL at 10, 18, 23 and 26y                                                                                                                                                               1st event unknown, 2nd LMB-89, 3rd R-CHOP, 4th DHAP                                                      Alive, CR at 27 y
                                                                                                                                                Pt2: DLBCL                                     Homozygous 657del5                                                                                                        14/F                                      DLBCL at 14, 20y                                                                                                                                                                          1st event unknown, 2nd LMB-89 without MTX                                                                Died of liver failure after CYM protocol at 20 y
                                                                                                                                                Pt3: DLBCL                                     Homozygous 657del5                                                                                                        4/F                                       NR                                                                                                                                                                                        LMB-89, without CTX, followed by individualized chemotherapy                                             Died of disease after second individual protocol at 5 y
                                                                                                                                                Pt4: DLBCL                                     Homozygous 657del5                                                                                                        6/F                                       NR                                                                                                                                                                                        LMB-89, without CTX                                                                                      Died of disease at 7 y
                                                                                                                                                Pt5: DLBCL                                     Homozygous 657del5                                                                                                        11/F                                      NR                                                                                                                                                                                        LMB-89 without CTX, followed by individualized chemotherapy                                              Died of disease at 12 y
                                                                                                                                                Pt6: DLBCL                                     Homozygous 657del5                                                                                                        23/M                                      Switch from DLBCL to AILT at 26y                                                                                                                                                          LMB-89; for AILT: BFM-90 followed by individualized chemotherapy                                         Died of disease after individual protocol at 27 y
                                                                                                                                                Pt7: BL                                        Homozygous 657del5                                                                                                        9/M                                       Burkit like lymphoma at 9, followed by DLBCL at 10                                                                                                                                        1st LMB-89, 2nd LMB-89 followed by individualized chemotherapy and splenectomy                           Alive at 16 y
                                                                                                                                                Pt8: BL                                        Homozygous 657del5                                                                                                        5/F                                       NR                                                                                                                                                                                        LMB-89                                                                                                   PR, alive at 12
  NBS                                                                     ([@B38])           11        NS                                       Pt1: DLBCL                                     NR                                                                                                                        9/M                                       NR                                                                                                                                                                                        NHL-BFM86                                                                                                CR 11 y after diagnosis
                                                                                                                                                Pt2: DLBCL                                     NR                                                                                                                        15/F                                      B-NHL at 31 y, third malignancy Bi-linage leukemia at 34 y                                                                                                                                NHL-BFM86 modified                                                                                       Died at 34y from 3rd malignancy
                                                                                                                                                Pt3: BL                                        NR                                                                                                                        4/M                                       2nd BL at 10 y                                                                                                                                                                            NHL-BFM90                                                                                                CR at 18y
                                                                                                                                                Pt4: IL                                        NR                                                                                                                        10/F                                      NR                                                                                                                                                                                        NHL-BFM90 switched to CHOP because of progressive disease                                                Died 4.5 m after diagnosis
                                                                                                                                                Pt5: FL                                        NR                                                                                                                        7/F                                       2nd DLBCL 13 m after diagnosis, third NHL (DLBCL) 8 y after diagnosis                                                                                                                     NHL-BFM95                                                                                                Current under treatment (NHL-BFM modified)
                                                                                                                                                Pt6; BL                                        NR                                                                                                                        5/M                                       NR                                                                                                                                                                                        NHL-BFM95                                                                                                CR 6 y after diagnosis
                                                                                                                                                Pt7: DLBCL                                     NR                                                                                                                        5/F                                       2nd malignancy: ALCL-T 3.5 y after diagnosis                                                                                                                                              NHL-BFM95 modified                                                                                       Death of lung infection 8 y after diagnosis
                                                                                                                                                Pt8: DLBCL                                     NR                                                                                                                        15/M                                      NR                                                                                                                                                                                        NHL-BFM95 + Rituximab                                                                                    CR 4 y after diagnosis
                                                                                                                                                Pt9: NHL                                       NR                                                                                                                        10/F                                      NR                                                                                                                                                                                        NHL-BFM95 modified                                                                                       Death of lung infection 1 m after end of treatment
                                                                                                                                                Pt10: DLBCL                                    NR                                                                                                                        9/F                                       2nd malignancy: T-ALL 3.5 y after diagnosis                                                                                                                                               B-NHL BFM04 modified + Rituximab                                                                         Death during treatment, 8 m after diagnosis of T-ALL
                                                                                                                                                Pt11: ALCL                                     NR                                                                                                                        15/M                                      NR                                                                                                                                                                                        NHL-BFM90                                                                                                CR 6 y after diagnosis
  Ataxia Telangiectasia                                                   ([@B38])           11        NS                                       Pt1: BL                                        NR                                                                                                                        16/M                                      NR                                                                                                                                                                                        B-NHL-BFM04 modified                                                                                     Chronic lung disease, death of pulmonal infection 1.9 y after diagnosis
                                                                                                                                                Pt2: BL                                        NR                                                                                                                        7/M                                       NR                                                                                                                                                                                        B-NHL BFM04 modified + Rituximab-Window                                                                  CR 2.7 y after diagnosis
                                                                                                                                                Pt3: DLBCL                                     NR                                                                                                                        6/M                                       NR                                                                                                                                                                                        B-NHL BFM04 modified                                                                                     CR 3.8 y after diagnosis
                                                                                                                                                Pt4: DLBCL                                     NR                                                                                                                        9/F                                       NR                                                                                                                                                                                        NHL-BFM90 modified                                                                                       Death of early relapse 1 y after diagnosis
                                                                                                                                                Pt5: DLBCL                                     NR                                                                                                                        5/M                                       2nd malignancy: DLBCL 10 y after diagnosis                                                                                                                                                NHL-BFM95 modified                                                                                       CR
                                                                                                                                                Pt6: DLBCL                                     NR                                                                                                                        11/M                                      2nd malignancy: DLBCL 3 y after diagnosis                                                                                                                                                 NHL-BFM95 modified                                                                                       Death with pulmonary failure
                                                                                                                                                Pt7: DLBCL                                     NR                                                                                                                        7/F                                       NR                                                                                                                                                                                        NHL BFM95 modified                                                                                       CR 9.6 y after diagnosis
                                                                                                                                                Pt8: DLBCL                                     NR                                                                                                                        10/F                                      NR                                                                                                                                                                                        NHL-BFM95 modified                                                                                       Death of therapy toxicity 4 m after diagnosis
                                                                                                                                                Pt9: DLBCL                                     NR                                                                                                                        9/M                                       NR                                                                                                                                                                                        NHL-BFM95 modified                                                                                       CR 7.1 y after diagnosis
                                                                                                                                                Pt10: DLBCL                                    NR                                                                                                                        9/F                                       NR                                                                                                                                                                                        NHL-BFM95 modified                                                                                       CR 7 y after diagnosis
                                                                                                                                                Pt11: HL                                       NR                                                                                                                        12/M                                      NR                                                                                                                                                                                        No chemotherapy                                                                                          Death of progressive disease 1 m after diagnosis
  NBS                                                                     ([@B39])           10/26     Defective antitumor immunosurveillance   Pt1: NHL                                       NR                                                                                                                        5/F                                       NR                                                                                                                                                                                        NR                                                                                                       NR
                                                                                                                                                Pt2: NHL                                       NR                                                                                                                        8/F                                       NR                                                                                                                                                                                        NR                                                                                                       Death at 10 y
                                                                                                                                                Pt3: NHL                                       NR                                                                                                                        7/F                                       NR                                                                                                                                                                                        NR                                                                                                       Death at 7 y
                                                                                                                                                Pt4: NHL                                       NR                                                                                                                        12/F                                      NR                                                                                                                                                                                        NR                                                                                                       Death at 12 y
                                                                                                                                                Pt5: NHL                                       NR                                                                                                                        7/F                                       NR                                                                                                                                                                                        NR                                                                                                       Death at 10 y
                                                                                                                                                Pt6: NHL                                       NR                                                                                                                        7/F                                       NR                                                                                                                                                                                        NR                                                                                                       Death at 19 y
                                                                                                                                                Pt7: NHL                                       NR                                                                                                                        7/F                                       NR                                                                                                                                                                                        NR                                                                                                       Death at 7 y
                                                                                                                                                Pt8: NHL                                       NR                                                                                                                        11/M                                      NR                                                                                                                                                                                        NR                                                                                                       NR
                                                                                                                                                Pt9: NHL                                       NR                                                                                                                        29/F                                      NR                                                                                                                                                                                        NR                                                                                                       Death at 29 y
                                                                                                                                                Pt10: HL                                       NR                                                                                                                        12/M                                      NR                                                                                                                                                                                        NR                                                                                                       Death at 14 y
  NBS[^\*^](#TN1){ref-type="table-fn"}                                    ([@B40])           11        Two cases possibly EBV associated        Pt1: BL                                        NR                                                                                                                        9/M                                       Abdominal, splenomegaly (cervical tumor)                                                                                                                                                  NR                                                                                                       Alive at 15 y
                                                                                                                                                Pt2: DLBCL                                     NR                                                                                                                        24/M                                      Abdominal (inguinal LN)                                                                                                                                                                   NR                                                                                                       Died at 27 y
                                                                                                                                                Pt3: DLBCL                                     NR                                                                                                                        11/F                                      Generalized (axillary LN)                                                                                                                                                                 NR                                                                                                       Died at 12 y
                                                                                                                                                Pt4: DLBCL                                     NR                                                                                                                        6/F                                       Cervical LN                                                                                                                                                                               NR                                                                                                       Died at 7 y
                                                                                                                                                Pt5: DLBCL                                     NR                                                                                                                        4/F                                       Cervical LN                                                                                                                                                                               NR                                                                                                       Died at 6 y
                                                                                                                                                Pt6: DLBCL                                     NR                                                                                                                        15/F                                      Generalized (axillary LN)                                                                                                                                                                 NR                                                                                                       Died at 20 y
                                                                                                                                                Pt7: DLBCL                                     NR                                                                                                                        11/M                                      Cervical LN                                                                                                                                                                               NR                                                                                                       Alive at 27 y
                                                                                                                                                Pt8: DLBCL                                     NR                                                                                                                        4/M                                       Generalized cervical LN                                                                                                                                                                   NR                                                                                                       Died at 5 y
                                                                                                                                                Pt9: DLBCL                                     NR                                                                                                                        8/F                                       Generalized (axillary LN)                                                                                                                                                                 NR                                                                                                       Died at 10 y
                                                                                                                                                Pt10: HL                                       NR                                                                                                                        12/M                                      Cervical LN                                                                                                                                                                               NR                                                                                                       Died at 14 y
                                                                                                                                                Pt11: AILT-like                                NR                                                                                                                        8/F                                       Generalized cervical LN                                                                                                                                                                   NR                                                                                                       Died at 8 y
  NBS                                                                     ([@B41])           4         NS                                       Pt1: DLBCL                                     NR                                                                                                                        15/F                                                                                                                                                                                                                                NHL-BFM                                                                                                  CR, LFU +6 y
                                                                                                                                                Pt2: ALCL (B)                                  NR                                                                                                                        6/F                                                                                                                                                                                                                                 NHL-BFM                                                                                                  Death of fungal sepsis after first course of therapy
                                                                                                                                                Pt3: DLBCL                                     NR                                                                                                                        9/M                                                                                                                                                                                                                                 NHL-BFM                                                                                                  CR, LFU +2.5 y
                                                                                                                                                Pt4: IL                                        NR                                                                                                                        10/F                                                                                                                                                                                                                                NHL-BFM + RT                                                                                             Initial nonresponse died after 5 m
  NBS                                                                     ([@B42])           1         Defective DNA repair                     DLBCL                                          Homozygous 657del5                                                                                                        17/M                                      Bilateral cervical LN, malaise, headache, epistaxis, symptoms of URI, fever, night sweats, and loss of weight, followed by the development of protruding tissue mass in the epigastrium   Modified CHOP + Rituximab                                                                                CR, 3 y in CR on LFU
  NBS[^\*^](#TN1){ref-type="table-fn"}                                    ([@B43])           1         EBV associated                           HL                                             Homozygous 657del5                                                                                                        5/F                                       Fever lasting for 2 m and mediastinal adenopathy                                                                                                                                          COPP/ABV                                                                                                 CR, 2 y in CR on LFU
  NBS[^\*^](#TN1){ref-type="table-fn"}                                    ([@B44])           12/57     Chronic antigenic stimulation            NHL                                            NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       15 out of total 22 patients died, but 7 were clinically stable after early diagnosis and successful treatment
                                                                                             2/57      Chronic antigenic stimulation            HL                                             NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       
  NBS                                                                     ([@B45])           30/149    NS                                       NHL                                            NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       44% of all patients in CR, 54% dead due to disease progression
                                                                                             7/149                                              HL                                             NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       
  Dyskeratosis Congenita                                                  ([@B46])           1         Genetic insatiability                    HL                                             NR                                                                                                                        30/M                                      NR                                                                                                                                                                                        Radiation-chemotherapy                                                                                   Died after 25 y (gastric adenocarcinoma)
  Ataxia Telangiectasia                                                   ([@B3])            1/10      NS                                       1 NHL                                          NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       NR
  Ataxia Telangiectasia                                                   ([@B41])           2         NS                                       Pt1: DLBCL                                     NR                                                                                                                        9/F                                                                                                                                                                                                                                 NHL-BFM                                                                                                  Relapse after 10 m, died after 1 y of diagnosis
                                                                                                       NS                                       Pt2: DLBCL                                     NR                                                                                                                        12/M                                                                                                                                                                                                                                NHL-BFM                                                                                                  CR, LFU +1 y
  PNP deficiency                                                          ([@B41])           1         NS                                       ALCL (B)                                       NR                                                                                                                        2/F                                                                                                                                                                                                                                 dosages reduced                                                                                          BMT (haploident.) in CR, BMT-related death
  Schimke Immuno-Osseous dysplasia                                        ([@B47])           1         NR                                       NHL                                            SMARCAL1 missense mutation (R561H)                                                                                        8/M                                       Colicky abdominal pain and vomiting. Palpation of the abdomen revealed a hard mass in right upper abdomen. Intussusception secondary to NHL                                               Vincristine, cyclophosphamide, adriamycin and intrathecal methotrexate using half of their usual doses   Died due to septicemia following chemotherapy
  Schimke Immuno-Osseous dysplasia                                        ([@B48])           3/71      NS                                       NHL                                            SMARCAL mutation                                                                                                          NR                                        NR                                                                                                                                                                                        NR                                                                                                       NR
  Schimke Immuno-Osseous dysplasia[^\*^](#TN1){ref-type="table-fn"}       ([@B49])           1         EBV associated                           BCL                                            Homozygous mutation of the SMARCAL1 gene (1146--1147delAA þ IVS6 þ 2delGT)                                                5/M                                       Fever, mild cough                                                                                                                                                                         Chemotherapy                                                                                             Died 1 m later due to multiorgan failure
  CHARGE association with Hyper-IgM                                       ([@B50])           1         Chronic antigenic stimulation            MZL                                            NR                                                                                                                        5/F                                       Suspected purulent bilateral conjunctivitis: Unresponsive On microscopy: salmon-colored, nodular lesions                                                                                  Topical IFN-\[alpha\] 3 times a day 300,000 U/drop.                                                      Resolved. No lesions at 1 y FU
  **PREDOMINANTLY ANTIBODY DEFICIENCIES**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Severe Ig deficiency                                                    ([@B41])           1         NS                                       DLBCL                                          NR                                                                                                                        14/F                                                                                                                                                                                                                                VBL for palliation only                                                                                  Died after 3 m
  IgG1, −3 and −4 deficiency                                              ([@B41])           1         NS                                       BL                                             NR                                                                                                                        6/F                                                                                                                                                                                                                                 NHL-BFM                                                                                                  CR, LFU +5 y
  Selective IgA deficiency                                                ([@B41])           1         NS                                       Burkitt-like                                   NR                                                                                                                        2/M                                                                                                                                                                                                                                 NHL-BFM                                                                                                  CR, LFU +0.5 y
  IgG-4 and IgM deficiency                                                ([@B41])           1         NS                                       BL                                             NR                                                                                                                        5/F                                                                                                                                                                                                                                 B-NHL therapy per protocol full dosage                                                                   CR, LFU +4.5 y
  IgA, IgG2, and −4 deficiency                                            ([@B41])           1         NS                                       BL                                             NR                                                                                                                        11/M                                                                                                                                                                                                                                NHL-BFM                                                                                                  Reached CR, died of sepsis after second therapy course
  APDS                                                                    ([@B51])           2/8       NS                                       Pt1: DLBCL                                     GOF mutation in the PIK3CD gene: E1021K (c.3061G \> A)                                                                    8/M                                       2nd DLBCL at 19 y                                                                                                                                                                         Initially UKCCSG 9002 protocol, 2nd malignancy: CHOP + Rituximab                                         Died from large bowel perforation and bleeding 12 days after the third course of chemotherapy.
                                                                                                                                                Pt2: HL                                        Heterozygous GOF mutation in the PIK3CD gene: E1021K                                                                      11/M                                      Cervical LN enlargement                                                                                                                                                                   Chemotherapy and RT                                                                                      CR, alive FU of more than 10 y
  APDS                                                                    ([@B52])           6/53      NS                                       2 DLBCL, 1 HL, 1 NMZL,1 Hodgkin-like           E1021K mutation                                                                                                           1.5--27/NR                                NR                                                                                                                                                                                        NR                                                                                                       3 died
  APDS                                                                    ([@B53])           1/17      NS                                       MZL                                            E1021K mutation                                                                                                           NR                                        NR                                                                                                                                                                                        NR                                                                                                       NR
  Selective IgA deficiency                                                ([@B54])           1/386     NS                                       NHL                                            NR                                                                                                                        38/M                                      NR                                                                                                                                                                                        NR                                                                                                       NR
  CVID                                                                    ([@B55])           1         NS                                       DHL                                            NR                                                                                                                        47/M                                      Abd pain, numbness, and weakness in legs.                                                                                                                                                 RT, cyclophosphamide, vincristine, procarbazine, prednisone                                              FU 3.5 y: CR
  CVID                                                                    ([@B56])           1         NS                                       EZMZL                                                                                                                                                                    16/F                                      Cough, wheezing                                                                                                                                                                           Prednisolone                                                                                             Alive
  CVID                                                                    ([@B57])           1         NS                                       EZMZL                                                                                                                                                                    44/F                                                                                                                                                                                                                                Chlorambucil and prednisone                                                                              Recurrence after 6m
  CVID                                                                    ([@B58])           54        EBV possibly                             BCL                                            NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       NR
  CVID[^\*^](#TN1){ref-type="table-fn"}                                   ([@B59])           3/220     EBV associated                           BCL                                            NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       NR
  CVID                                                                    ([@B60])           7         NS                                       BCL                                            NR                                                                                                                        46[^\*\*^](#TN2){ref-type="table-fn"}/F   NR                                                                                                                                                                                        NR                                                                                                       NR
                                                                                             9         NS                                       BCL                                            NR                                                                                                                        42[^\*\*^](#TN2){ref-type="table-fn"}/M   NR                                                                                                                                                                                        NR                                                                                                       NR
  CVID[^\*^](#TN1){ref-type="table-fn"}                                   ([@B61])           1         EBV or ITK mutation                      HL                                             NR                                                                                                                        25/F                                      NR                                                                                                                                                                                        Rituximab and brentuximab vedotin.                                                                       CR
  CVID                                                                    ([@B62])           3         NS                                       Pt1: BCL                                       NR                                                                                                                        2/M                                       Generalized LN                                                                                                                                                                            NR                                                                                                       Died at 23y
                                                                                                                                                Pt2: BCL                                       NR                                                                                                                        61/F                                      NR                                                                                                                                                                                        NR                                                                                                       NR
                                                                                                                                                Pt3: BCL                                       NR                                                                                                                        66/F                                      NR                                                                                                                                                                                        NR                                                                                                       NR
  CVID                                                                    ([@B63])           22/248    NS                                       Pt1: NHL                                       NR                                                                                                                        13/F                                      NR                                                                                                                                                                                        Chemotherapy (CHOP)                                                                                      Died, age 13
                                                                                                                                                Pt2: NHL                                       NR                                                                                                                        31/F                                      NR                                                                                                                                                                                        Surgery                                                                                                  Alive 1 y later
                                                                                                                                                Pt3: NHL                                       NR                                                                                                                        41/M                                      NR                                                                                                                                                                                        Chemotherapy, HSCT                                                                                       Died, age 41
                                                                                                                                                Pt4: NHL                                       NR                                                                                                                        44/F                                      NR                                                                                                                                                                                        Surgery                                                                                                  Unknown, alive 8 y later
                                                                                                                                                Pt5: NHL                                       NR                                                                                                                        45/M                                      NR                                                                                                                                                                                        None                                                                                                     Alive, 1 y later
                                                                                                                                                Pt6: NHL                                       NR                                                                                                                        46/F                                      NR                                                                                                                                                                                        Chemotherapy (Type?)                                                                                     Died
                                                                                                                                                Pt7: NHL                                       NR                                                                                                                        48/M                                      NR                                                                                                                                                                                        None                                                                                                     Died, age 48
                                                                                                                                                Pt8: NHL                                       NR                                                                                                                        52/F                                      NR                                                                                                                                                                                        Chemotherapy (CHOP)                                                                                      Died, age 56
                                                                                                                                                Pt9: NHL                                       NR                                                                                                                        52/F                                      NR                                                                                                                                                                                        Radiation                                                                                                Alive, 2 y later
                                                                                                                                                Pt10: NHL                                      NR                                                                                                                        54/F                                      NR                                                                                                                                                                                        Surgery, surgery, chemotherapy                                                                           Alive at age 68
                                                                                                                                                Pt11: NHL                                      NR                                                                                                                        54/F                                      NR                                                                                                                                                                                        Surgery                                                                                                  Died other causes, 15 y later, age 69
                                                                                                                                                Pt12: NHL                                      NR                                                                                                                        56/F                                      NR                                                                                                                                                                                        M-BACOD, CHOP, RT, CP                                                                                    Alive, 12 y later
                                                                                                                                                Pt13: NHL                                      NR                                                                                                                        63/M                                      NR                                                                                                                                                                                        CHOP, M-BACOD, M2                                                                                        Died, age 65
                                                                                                                                                Pt14: NHL                                      NR                                                                                                                        67/F                                      NR                                                                                                                                                                                        Chemotherapy (C-MOPP)                                                                                    Died, age 68
                                                                                                                                                Pt15: NHL                                      NR                                                                                                                        67/F                                      NR                                                                                                                                                                                        Chemotherapy (CHOP)                                                                                      Alive, stable 8 y later
                                                                                                                                                Pt16: NHL                                      NR                                                                                                                        71/F                                      NR                                                                                                                                                                                        Chemotherapy (C-MOPP)                                                                                    Died, age 72
                                                                                                                                                Pt17: NHL                                      NR                                                                                                                        72/F                                      NR                                                                                                                                                                                        Alpha interferon                                                                                         Died, age 73
                                                                                                                                                Pt18: NHL                                      NR                                                                                                                        75/F                                      NR                                                                                                                                                                                        Radiation                                                                                                Alive, stable, 2 y later
                                                                                                                                                Pt19: NHL                                      NR                                                                                                                        77/M                                      NR                                                                                                                                                                                        Chemotherapy (Type?)                                                                                     Died, age 77
                                                                                                                                                Pt20, Pt 21, Pt 22: HL                         NR                                                                                                                        8/M Rest NR                               NR                                                                                                                                                                                        Splenectomy and chemotherapy in Pt20                                                                     Pt20 relapsed after 12 years
  CVID                                                                    ([@B64])           5/5       NS                                       Pt1: EZMZL                                     NR                                                                                                                        56/F                                      Parotid, 2nd Breast, 3rd DLBCL in sternum after 11 y                                                                                                                                      Radiation, excision, CHOP, rituximab                                                                     Recurrence
                                                                                                                                                Pt2: EZMZL                                     NR                                                                                                                        35/F                                      Lung                                                                                                                                                                                      None                                                                                                     Well
                                                                                                                                                Pt3: EZMZL                                     NR                                                                                                                        31/F                                      Parotid                                                                                                                                                                                   Excision, radiation                                                                                      Recurrence
                                                                                                                                                Pt4: EZMZL                                     NR                                                                                                                        42/M                                      Lung involvement                                                                                                                                                                          CVP and Rituximab 2, CHOP                                                                                Recurrence
                                                                                                                                                Pt5: EZMZL                                     NR                                                                                                                        35/F                                      Lung                                                                                                                                                                                      R-CHOP                                                                                                   CR
  CVID                                                                    ([@B65], [@B66])   9/117     Unknown                                  Pt1: DLBCL                                     NR                                                                                                                        12/F                                      Liver, Spleen                                                                                                                                                                             CHOP                                                                                                     Died at 13 y
                                                                                                                                                Pt2: DMSL                                      NR                                                                                                                        54/F                                      Right Inguinal Node                                                                                                                                                                       CHOP                                                                                                     Died at 69 due to other causes
                                                                                                                                                Pt3: DMSL                                      NR                                                                                                                        50/F                                      Pelvis,                                                                                                                                                                                   CHOP                                                                                                     Died at 56 y
                                                                                                                                                Pt4: DLBCL                                     NR                                                                                                                        48/F                                      Proximal jejunum                                                                                                                                                                          Surgery                                                                                                  Alive, 8 y later
                                                                                                                                                Pt5: Follicular                                NR                                                                                                                        54/F                                      Parotid, 1 y later FL in axilla                                                                                                                                                           Surgery for both                                                                                         Alive, after 3 y
                                                                                                                                                Pt6: diffuse small cleaved cell                NR                                                                                                                        56/F                                      Pelvic nodes                                                                                                                                                                              M-BACOD, CHOP, RT, CP                                                                                    Alive
                                                                                                                                                Pt7: DLBCL                                     NR                                                                                                                        57/F                                      Supraclavicular area, abdomen                                                                                                                                                             C-MOPP                                                                                                   Died at age 68
                                                                                                                                                Pt8: DLBCL                                     NR                                                                                                                        65/F                                      Lymph nodes, lungs                                                                                                                                                                        C-MOPP                                                                                                   Died at age 72
                                                                                                                                                Pt9: DLBCL                                     NR                                                                                                                        70/F                                      Cervical lymph nodes                                                                                                                                                                      Alpha-Interferon                                                                                         Alive
  CVID                                                                    ([@B54])           5/176     NS                                       Pt1: NHL                                       NR                                                                                                                        52/F                                      NR                                                                                                                                                                                        NR                                                                                                       NR
                                                                                                                                                Pt2: NHL                                       NR                                                                                                                        59/F                                      NR                                                                                                                                                                                        NR                                                                                                       NR
                                                                                                                                                Pt3: NHL                                       NR                                                                                                                        76/F                                      NR                                                                                                                                                                                        NR                                                                                                       NR
                                                                                                                                                Pt4: HL                                        NR                                                                                                                        49/F                                      NR                                                                                                                                                                                        NR                                                                                                       NR
  CVID                                                                    ([@B67])           1         Defective antitumor immunosurveillance   DHL                                            NR                                                                                                                        44/F                                      Abd. pain, slight diarrhea, weight loss. Palpable mass in right abdomen                                                                                                                   Resection and irradiation                                                                                4-y F/U: CR
  CVID                                                                    ([@B68])           1         Chronic antigenic stimulation            IL                                             NR                                                                                                                        75/W                                      Weight loss, numbness and tingling in extremities                                                                                                                                         Surgical resection                                                                                       Death post-op due to septicemia
  CVID                                                                    ([@B69])           1         Defective antitumor immunosurveillance   MZL                                            NR                                                                                                                        39/M                                      Periumbilical pain, severe diarrhea, weight loss                                                                                                                                          NR                                                                                                       NR
  CVID                                                                    ([@B70])           4/224     NS                                       NHL                                            NR                                                                                                                        NR                                        NR                                                                                                                                                                                        Chemotherapy + Rituximab + transplant                                                                    NR
  CVID                                                                    ([@B71])           5/247     NS                                       Jejunal, 1 histiocytic, 1 HL, 2 BCL            NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       4 died, HL responded to RT
  CVID[^\*^](#TN1){ref-type="table-fn"}                                   ([@B72])           1         NS                                       EMZL                                           NR                                                                                                                        41/F                                      Malaise, dyspnea and productive cough                                                                                                                                                     IVIG, chlorambucil and prednisone                                                                        
  CVID                                                                    ([@B73])           10/334    NS                                       NHL                                            NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       5 died.
  CVID                                                                    ([@B3])            10/416    NS                                       1 DLBCL, 2 FL,1 BL, 1 SLL,1 EMZL, 3 NHL,1 WM   NR                                                                                                                        NR                                        NR                                                                                                                                                                                        NR                                                                                                       NR
  CVID                                                                    ([@B74])           23        NR                                       NHL                                            NR                                                                                                                        NR/28F, 11M                               NR                                                                                                                                                                                                                                                                                                 11 died of lymphoma, 12 alive
                                                                                             3         NR                                       DLBCL                                          NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                     2 died of lymphoma, 1 also had severe lung disease, 1 alive
                                                                                             4         NR                                       HL                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                     2 died of lymphoma, 2 alive
                                                                                             5         NR                                       EMZL                                           NR                                                                                                                                                                                                                                                                                                                                                            3 no treatment, 2 chemotherapy                                                                           All alive
                                                                                             1         NR                                       MZL                                            NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                     No treatment given, alive
                                                                                             1         NR                                       Diffuse poorly differentiated                  NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Died of lymphoma
                                                                                             1         EBV associated                           T -cell rich BCL                               NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Died of lymphoma
  Selective IgA deficiency                                                ([@B75])           1         Chronic antigenic stimulation            PCMZL, MZL                                     MZL: monoclonal amplification of 98 base pairs in FR3A region of the IGH gene                                             43/F                                      Asymptomatic subcutaneous nodules in upper extremity. Enlarged axillary, mediastinal LN                                                                                                   RituximabRadiotherapy and local excision                                                                 CR followed by repetitive relapses
  **DISEASES OF IMMUNE DYSREGULATION**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ALPS[^\*^](#TN1){ref-type="table-fn"}                                   ([@B76])           1         EBV associated                           FL, DLBCL, HL                                  c.784A\>T mutation in TNFRSF6,                                                                                            33/M                                      Lymphadenopathy                                                                                                                                                                           R-CHOP                                                                                                   CR
  XLP1                                                                    ([@B77])           3         Defective antitumor immunosurveillance   Pt1: BL                                        SH2D1A p.E17D c.51 G \> C                                                                                                 6/M                                       Acute abd. obstruction on presentation, night sweats, weight loss.                                                                                                                        NHL-BFM95, full dosage, + Rituximab                                                                      CR
                                                                                                                                                Pt2: DLBCL                                     SH2D1A p.W64C c.192G \> T                                                                                                 14/M                                      Painless mass of about 2.0 × 2.5 cm in size on the front right-side chest wall                                                                                                            B-NHL-M2004, full dosage + Rituximab                                                                     Died at the age of 19
                                                                                                                                                Pt3: DLBCL                                     SH2D1A c.53insA \> T                                                                                                      6/M                                       Testicular DLBCL                                                                                                                                                                          NHL-BFM90 + Rituximab                                                                                    Died at 8.3 y
  XLP1[^\*^](#TN1){ref-type="table-fn"}                                   ([@B78])           1         NS                                       BL                                             exon 2 of the SH2D1A gene at position 146 (c146insG                                                                       4/M                                       Lymphadenopathy, HS, cerebellar tumor                                                                                                                                                     ETO, DXM, cyclophosphamide                                                                               PR died of ICH
  XLP[^\*^](#TN1){ref-type="table-fn"}                                    ([@B79])           2         EBV associated                           Pt1: BL                                        NR                                                                                                                        1.6/M                                     Palpable abd. mass Malaise, poor appetite, failure to thrive.                                                                                                                             Protocol LMB-84                                                                                          Died of hemorrhage 6 m after stopping therapy.
                                                                                                                                                Pt2: BL                                        t(8;14) (q24;q32)                                                                                                         2/M                                       Abd. Mass, malaise and failure to thrive.                                                                                                                                                 Protocol LMB-84                                                                                          Relapse after 17 m. Died.
  ITK deficiency[^\*^](#TN1){ref-type="table-fn"}                         ([@B80])           1         EBV associated                           HL                                             48, X,X,+2,der(10)add(10)(p13) add(10)(q34),del(11)(q22q23), + 12,-13, + 1B2mar                                           5/F                                       Cervical and inguinal lymphadenopathy                                                                                                                                                     IFS, vinorelbine, etoposide, cytarabine, gemcitabine) RT, HSCT                                           CR
  ITK deficiency[^\*^](#TN1){ref-type="table-fn"}                         ([@B81])           2         EBV associated                           Pt1: NHL                                       NS                                                                                                                        6/F                                       Cervical and occipital Lymphadenopathy                                                                                                                                                    CHOP and anti CD20 Ab                                                                                    Died of infection
                                                                                                                                                P2: HL                                         NS                                                                                                                        2.5/M                                     NR                                                                                                                                                                                        Chemotherapy                                                                                             NR
  ITK deficiency[^\*^](#TN1){ref-type="table-fn"}                         ([@B82])           1         EBV associated                           HL                                             NS                                                                                                                                                                  Lung and Kidney                                                                                                                                                                           HSCT, Rituximab, Fludarabine, Melphalan, ATG                                                             CR
  ITK deficiency[^\*^](#TN1){ref-type="table-fn"}                         ([@B83])           4         EBV associated                           Pt1: HL                                        IKT gene: 1764C\>G: YS886                                                                                                 4/F                                       LN                                                                                                                                                                                        NR                                                                                                       Died at age 6
                                                                                                                                                Pt2: HL                                        IKT gene: 1764C\>G: YS886                                                                                                 5/M                                       LN                                                                                                                                                                                        Induction Therapy                                                                                        PreHSCT, age 10
                                                                                                                                                Pt3: HL                                        IKT gene: 1764C\>G: YS886                                                                                                 3/M                                       LN                                                                                                                                                                                        HSCT                                                                                                     Alive
                                                                                                                                                Pt4: DLBCL                                     IKT gene: 1497delT: D500T, F501L, MS03X                                                                                   6/F                                       Lungs                                                                                                                                                                                     HSCT                                                                                                     Died from GVHD in 6 m
  ITK deficiency[^\*^](#TN1){ref-type="table-fn"}                         ([@B84])           3         EBV associated                           Pt1: HL                                        ITK gene: single homozygous mutation c. 1764 C-\>G which causes a premature stop-codon Y588X                              5/F                                       Lymphadenopathy and Hepatosplenomegaly                                                                                                                                                    Rituximab, VP-16, vinorelbine, GMC                                                                       Died of respiratory failure
                                                                                                                                                Pt2: HL                                                                                                                                                                  5/M                                       Lymphadenopathy                                                                                                                                                                           Chemotherapy                                                                                             CR
                                                                                                                                                Pt3: HL                                                                                                                                                                  3/M                                       Lymphadenopathy and HS                                                                                                                                                                    HSCT with fludarabine, melphalan, ATG, rituximab                                                         Alive
  ITK deficiency[^\*^](#TN1){ref-type="table-fn"}                         ([@B85])           2         EBV associated                           Pt1: HL                                        Homozygous mutation in ITK on ch 5q31--5q32.                                                                              6/F                                       Generalized LN, HS, nasal, concha tumor                                                                                                                                                   Prednisone, procarbazine, vincristine, cyclophosphamide, ADM + rituximab                                 Died of respiratory failure at 10
                                                                                                                                                Pt2: HL                                        homozygous mutation in ITK 5q31--5q32.                                                                                    1/F                                       Retroperitoneal and abd. LN, HS                                                                                                                                                           GNC, steroid, rituximab, HSCT                                                                            Died of ischemic brain injury
  CD70 deficiency[^\*^](#TN1){ref-type="table-fn"}                        ([@B86])           1         EBV associated                           HL                                                                                                                                                                       3/M                                       Recurrent fever, lymphadenopathy, HS                                                                                                                                                      Initially chemotherapy and radiotherapy Rituximab at 4 HSCT at 10                                        CR after chemo/radiotherapy No relapse of HL, however recurrent lymphoproliferative episodes. Well since HSCT.
  CD70 deficiency[^\*^](#TN1){ref-type="table-fn"}                        ([@B87])           3         EBV associated                           Pt1: HL                                        Homozygous c.250delT resulting in p.S84Pfs27X                                                                             17/M                                      Peptic ulcer, gastritis, splenomegaly and lymphadenopathy                                                                                                                                 doxorubicin, bleomycin, vinblastine, and dacarbazine                                                     CR, F/U at 29 y: Stable
                                                                                                                                                Pt2: HL                                        Homozygous c.555_557delCTT resulting in p.F186del                                                                         2/M                                       Diffuse cervical lymphadenopathy                                                                                                                                                          Initially OPPA and COPP ABVD + radiotherapy after relapse                                                CR after ABVD/radiotherapy F/U at 16: CR
                                                                                                                                                Pt3: HL                                        Homozygous c.555_557delCTT resulting in p.F186del                                                                         3/M                                       Chronic cervical lymphadenopathy                                                                                                                                                          ABVD gemcitabine, vinorelbine, and brentuximab were followed by auto-HSCT                                Relapse after ABVD, CR after HSCT
  CD27 deficiency[^\*^](#TN1){ref-type="table-fn"}                        ([@B88])           5         EBV associated                           Pt1: DLBCL                                     Homozygous c.G158A, p.C53Y                                                                                                2/F                                       NR                                                                                                                                                                                        None                                                                                                     Died at 2 y
                                                                                                                                                Pt2: DLBCL                                     Homozygous c.G158A, p.C53Y                                                                                                22/F                                      NR                                                                                                                                                                                        CHOP                                                                                                     Died at 22
                                                                                                                                                Pt3: HL                                        Compound c.G24A, p.W8X; c.C319T p.R107C                                                                                   15/F                                      Persistent cervical lymphadenopathy                                                                                                                                                       EuroNet-PHL-C1                                                                                           Alive
                                                                                                                                                Pt4: HL                                        Homozygous c.G287A, p.C96Y                                                                                                ?/F                                       NR                                                                                                                                                                                        None                                                                                                     Died at 20 y
                                                                                                                                                Pt5: HL                                        Homozygous c.G287A, p.C96Y                                                                                                8/M                                       NR                                                                                                                                                                                        ABVD, radiotherapy                                                                                       CR
  XMEN[^\*^](#TN1){ref-type="table-fn"} (MAGT1 deficiency)                ([@B89], [@B90])   2         EBV associated                           1\. BL                                         g.43183delC                                                                                                               7/M                                       2nd malignancy at 14                                                                                                                                                                      NR                                                                                                       Alive at 16 y
                                                                                                                                                2\. HL                                         g.46604G\>T                                                                                                               17/NR                                     2nd malignancy at 22                                                                                                                                                                      HSCT                                                                                                     Died at 23 y of HSCT complications
  XMEN                                                                    ([@B91])           1         EBV associated (suspected)               DLBCL                                          c.712C \> T, p.R238X                                                                                                      57/M                                      Lymphadenopathy, HS and B-symptoms                                                                                                                                                        RCHOP, RGCVP                                                                                             Died at 58 y from DLBCL
  XMEN[^\*^](#TN1){ref-type="table-fn"}                                   ([@B92])           1         EBV associated                           HL                                             c.555dup, p. Tyr186Ilefs[^\*^](#TN1){ref-type="table-fn"}2                                                                15/M                                      Influenza-like symptoms                                                                                                                                                                   COPP and ABVD                                                                                            Alive at 17 y
  CTPS1 deficiency[^\*^](#TN1){ref-type="table-fn"}                       ([@B93])           2         EBV associated                           Pt1: NHL                                       NR                                                                                                                        6/F                                       NR                                                                                                                                                                                                                                                                                                 Died at 6 y
                                                                                                                                                Pt2: NHL                                       NR                                                                                                                        1/M                                       NR                                                                                                                                                                                        HSCT                                                                                                     Alive at 2 y
  Hypergammaglobulinemia                                                  ([@B41])           1         NS                                       DLBCL                                          NR                                                                                                                        1/F                                                                                                                                                                                                                                 No therapy received                                                                                      Died of disease progression after 6 m
  IL-10R deficiency                                                       ([@B94])           5         Defective antitumor immunosurveillance   Pt1: DLBCL                                     IL-10RB gene: homozygous missense in exon 2 (p.Y59C)                                                                      5/M                                       NR                                                                                                                                                                                        COP, COPADM 3 2, CYM 3 2                                                                                 Died of disease progression
                                                                                                                                                Pt2: DLBCL                                     IL-10RB gene: heterozygous composite frameshift mutation in exon 7 (F269fsX275) + missense mutation in exon 5 (p.W204C)   5/M                                       NR                                                                                                                                                                                        COP, R-COPADM                                                                                            Died during treatment
                                                                                                                                                Pt3: DLBCL                                     homozygous nonsense in exon 3 of IL-10RB (p. E141X)                                                                       6/M                                       NR                                                                                                                                                                                        COP, R-COPADM, R-CYM, HSCT                                                                               Remission, alive (+12 m)
                                                                                                                                                Pt4: DLBCL                                     homozygous del (g.11930-17413 del) in IL-10RB.                                                                            5/M                                       NR                                                                                                                                                                                        COP, COPADM, R-CYM, R-ICE                                                                                Remission, alive (+18 m)
                                                                                                                                                Pt5: DLBCL                                     Homozygous c.368-10 C.G in intron 3 of IL-10RA.                                                                           6/M                                       NR                                                                                                                                                                                        Up-front R prephase                                                                                      Remission, alive
  **DEFECTS IN INTRINSIC AND INNATE IMMUNITY**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Whim Syndrome[^\*^](#TN1){ref-type="table-fn"}                          ([@B95])           1         EBV associated                           BCL                                            NR                                                                                                                        30/M                                      Red dermal facial nodules Axillary mass Axillary, hilar, Inguinal LN                                                                                                                      6 cycles CHOP + G-CSF before each cycle                                                                  Resolved after 6 cycles.
  Whim Syndrome[^\*^](#TN1){ref-type="table-fn"}                          ([@B96])           1         EBV associated                           BCL                                            NR                                                                                                                        26/F                                      Fatal EBV+ B cell Lymphoma in the intestine and other organs.                                                                                                                             CHOP                                                                                                     No response. Died of perforation and hemorrhage

*Abd, (abdominal); ABVD, (doxorubicin \[Adriamycin\], bleomycin, vinblastine, and dacarbazine); AILT, (angioimmunoblastic T cell lymphoma); APO, (doxorubicin, vincristine, 6-MP, and prednisone); APDS, (activated phosphoinositide 3-kinase d syndrome); BCL, (B cell lymphoma); BL, (Burkitt lymphoma); ALPS, (Autoimmune lymphoproliferative syndrome); COP, (cyclophosphamide, vincristine, prednisone); COPADM, (cyclophosphamide, vincristine, prednisone, doxorubicin, methotrexate); CHOP, (cyclophosphamide, adriamycin, vincristine, prednisolone); COPP, (Cyclophosphamide, Oncovin, Procarbazine, Prednisone); CP, (cis-platinum); C-MOPP, (cyclophosphamide, oncovin, procarbazine, prednisone); CYM, (cytarabine, methotrexate); DHL, (diffuse histiocytic lymphoma); EMZL, (extra nodal marginal zone lymphoma); F, (female); G-CSF, (Granulocyte colony-stimulating factor); HLH, (hemophagocytic lymphohistiocytosis); ICE, (ifosfamide, carboplatin, etoposide); IL, (immunoblastic lymphoma); INHL, (immunoblastic NHL); LFU, (last follow up); LN, (lymph node); LPD, (lymphoproliferative Disease); M, (male); m, (months); M-BACOD, (methotrexate, doxorubicin, cyclophosphamide, vincristine, dexamethasone); ML, (Malignant Lymphoma); M2, (vincristine, cyclophosphamide); NHL-BFM, (Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster); NHL, (Non-Hodgkin Lymphoma); NMZL, (nodal marginal zone lymphoma); LL, (lymphoplasmacytic lymphoma); n, (number of patients); OPPA, (Oncovin, procarbazine, prednisone, and doxorubicin); PDC, (plasmacytoid dendritic cells); pt, (patient); PCMZL, (primary cutaneous marginal zone lymphoma); PE, (Physical Examination); PTCL, (peripheral T cell lymphoma); RT, (radiation therapy); R, (Rituximab); WM, waldenstrom macroglobulinemia; XLP1, (X-linked lymphoproliferative disease type I); y, (years)*.

*EBV positive*,

*median age*.

B Cell Lymphomas in PIDDs {#s3}
=========================

A thorough search of the literature using Medline database (via PubMed; [Figure 1](#F1){ref-type="fig"}) identified 86 studies reporting B cell lymphoma in PIDD patients. [Table 1](#T1){ref-type="table"} gives details of the 456 patients identified from literature plus two unpublished cases from our center (Mayo Clinic, Rochester). The types of B cell lymphoma were unspecified non-Hodgkin Lymphoma (NHL) (37%, *n* = 171), diffuse large B cell lymphoma (DLBCL) (15%, *n* = 68), Hodgkin lymphoma (HL) (13%, *n* = 59), marginal zone lymphoma (MZL) including extranodal and intranodal MZL (5%, *n* = 23), Burkitt lymphoma (BL) (4%, *n* = 17) and diffuse histiocytic lymphoma (DHL) (0.4%, *n* = 2). Unlike T cell lymphomas where most of cases were reported in males, gender distribution was similar in males (29%, *n* = 130) and females (34%, *n* = 157), it was not specified (NS) in 37% (*n* = 169). The age of onset/diagnosis of lymphoma ranged from 7 months to 76 years (median age: 12 years). EBV association was seen in 25% (*n* = 113) of the patients. The majority of patients received combination chemotherapy as a standard treatment. While allogeneic hematopoietic cell transplantation (HCT) was not performed in many of these cases, it appeared to be successful in achieving a complete response (CR) in some cases. Serious infectious complications and death were frequently associated with chemotherapy treatment. Individual groups of PIDDs are examined in further detail based on the IUIS classification.

IUIS: Immunodeficiencies Affecting Cellular and Humoral Immunity
----------------------------------------------------------------

There were 12 studies which included 13 patients with B cell lymphoma. Adenosine deaminase 1 (ADA1) deficiency was most common immunodeficiency disease in this category ([@B19]--[@B24]). The other 7 cases include patients with an underlying diagnosis of Coronin 1A and DNA Ligase IV deficiencies, Artemis-SCID, RAG1, and ZAP70 defects ([@B13]--[@B18], [@B24], [@B107]). Of these 13 cases, 69% (*n* = 9) patients were females, 15% (*n* = 2) were males and 15% (*n* = 2) were NS. DLBCL (62%, *n* = 8) was the most common type of B cell neoplasm identified followed by unspecified B cell lymphoma (15%, *n* = 2). The median age at presentation was 1.5 years (range 0.9--14 years) and all patients were EBV-positive. The most common clinical presentation was lymphadenopathy and high fevers. The underlying etiology for the development of lymphoma appeared to be DNA repair defects and EBV association. All patients were treated with some form of combination chemotherapy, most commonly, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Of these 7 cases, only 2 patients survived and were in complete remission at follow-up. One patient who developed DLBCL in the setting of RAG1 deficiency had a partial response with rituximab, which was consolidated by HCT from an HLA-matched unrelated donor. Though there is no long-term follow-up data in this report, the patient had no evidence of disease at 3 years follow-up ([@B16]).

### Adenosine Deaminase 1 (ADA1) Deficiency

B cell lymphoma with ADA1 deficiency was seen in six patients, three of whom had EBV association ([@B19]--[@B24]). Only one patient was reported to be in complete remission 20 months after diagnosis, others died despite treatment.

IUIS: Combined Immunodeficiency Disorders With Associated or Syndromic Features
-------------------------------------------------------------------------------

In this category, 27 studies plus two unpublished cases reported B cell lymphomas in 191 patients with combined immunodeficiency disorders with associated or syndromic features. Of these, 41% (*n* = 78) cases were associated with EBV infection, and the lymphoma was diagnosed at median age of 10 years. In this cohort there appeared to be a preponderance of males at 38% (*n* = 73) with females accounting for 32% (*n* = 62) and 30% (*n* = 56). Some of the more common genetic disorders are discussed further.

### Ataxia Telangiectasia (AT)

Over one-third (35%, *n* = 67) of the reported cases of lymphoma in this IUIS category were in the setting of ataxia telangiectasia, which is an autosomal recessive disorder with immunodeficiency, DNA repair defects and neurological complications([@B3], [@B25]--[@B28], [@B38], [@B41]). Lymphomas were diagnosed across all ages of patients typically manifesting before 10 years of age with the oldest cases being reported at 16 years of age. Original reports reported the histology as DLBCL or unspecified NHL in 75% (*n* = 50), HL in 21% (*n* = 14), BL in 3% (*n* = 2), and MZL in 1% (*n* = 1) of cases. The most common presenting symptoms included extensive lymphadenopathy. A French study reported a crude incidence of cancer of 24.7% in AT with B cell lymphoid malignancies representing the majority of cases. The pathological diagnosis of lymphoma in these patients can be challenging, and it is relevant to note that three of the four T-cell NHLs, based on pathology, were reclassified as B-cell NHLs after centralized pathology review. The median overall survival (OS) decreased from 24 to 15 years in AT patients with malignant disease. In fact, the common causes of mortality in this group were either cancer (47%) or infectious complications (34%). There was a trend toward increased survival if there was an excellent response to chemotherapy. Though the overall prognosis in AT remains relatively poor, a subset of these of patients might benefit from treatment of the malignancy with an improved survival ([@B25]).

### Wiskott -Aldrich Syndrome (WAS)

There were 6 studies identified, which reported B cell lymphoma in 6 patients (median age 14 years) with WAS, which is an X-linked PIDD ([@B29]--[@B34]). DLBCL (33%, *n* = 2) was the most common type of B cell lymphoma in this group, followed by BL, HL, unspecified NHL and immunoblastic B cell lymphoma. As with many of the other PIDDs, EBV association was present in all these types. It is relevant to note that only 33% patients (*n* = 2, HL and Burkitt lymphoma) had complete remission on follow-up, while the others died of disease progression or its complications. In a multi-center cohort of X-linked thrombocytopenia (XLT) patients, certain *WAS* genetic variants associated with XLT, a milder form of WAS, predisposed to a higher incidence of developing lymphoma suggesting that these patients would benefit from treatment with HCT ([@B108]).

### DiGeorge Syndrome (DGS)

In this literature review, DGS did not appear to be associated with a high incidence of lymphomas, with only one reported case in a 10-month female who developed immunoblastic B cell NHL([@B35]). Similar to other PIDDs this case was also associated with EBV infection. The patient manifested multi-system complications with hemiparesis due to a cerebral mass, mediastinal lymphadenopathy, liver and kidney involvement, and succumbed to the disease prior to initiation of therapy.

### Cartilage Hair Hypoplasia (CHH)

CHH is a syndromic PIDD due to genetic defects in the *RMRP* gene and manifests with variable degree of immunodeficiency. While many patients who manifest with severe cellular immunodeficiency early in life may receive an HCT, patients with initially milder immunodeficiency may develop complications later in life, including malignancy. We identified 10 reported cases, with a median age of 29 years, equally divided between males and females. Majority of these cases were NHL (90%, *n* = 9) while the remaining (10%, *n* = 1) were HL. Interestingly, none of these were associated with EBV ([@B36]). This is in contrast to the 2 cases of adult CHH (male patients) in our center (unpublished, Mayo Clinic, Rochester), who were both EBV-positive and diagnosed in their 3rd to 4th decade of life. One of these patients was diagnosed with DLBCL after an incidental work-up of a lung nodule, while the other patient had MZL with recurrent fevers and night sweats. The patient with DLBCL was treated with R-CHOP and had CR, while the patients with MZL had recurrent disease, and was treated with rituximab. Therefore, like other PIDDs, CHH may also present with EBV-associated lymphomas, and it remains unclear if the EBV diagnosis could have been missed in other cases reported in the literature.

### Nijmegen Breakage Syndrome (NBS)

In this review strategy, 9 studies with 97 cases of lymphomas in patients with NBS were identified ([@B37]--[@B45]). NBS is a syndromic DNA repair defect, and in these published reports, 76% (*n* = 74) of patients presented with unclassified NHL and DLBCL. Most cases (82%, *n* = 80) were EBV-negative. The underlying DNA repair defect puts these patients at high risk, unless they receive HCT early after diagnosis.

### Dyskeratosis Congenita (DC)

Among the short telomere syndromes, while one would postulate high-risk of malignancy due to premature cellular senescence, this literature search only yielded a single case of an adult DC patient with HL not associated with EBV ([@B46]). The treatment strategy included combination chemotherapy and radiation, which likely was not appropriate in the context of the patient\'s underlying genetic defect, and presumed radiosensitivity, as the patient subsequently developed a gastric carcinoma and died of the disease. Short telomere syndromes are known to be associated with radiosensitivity, and therefore, radiation therapy is probably not a recommended treatment modality in this group, as well as in the patients with DNA repair defects.

### Schimke Immuno-Osseous dysplasia

We identified 3 studies, with 5 cases of B cell lymphoma ([@B47]--[@B49]). EBV association was seen in a single case (20%, *n* = 1). Outcome data was given for two patients, both of whom died with complications soon after starting chemotherapy.

### CHARGE Association With Hyper IgM Syndrome

We identified one report of a 5-year-old girl, with nonclassical CHARGE association and elevated IgM levels who developed bilateral extranodal (ocular) MZL. She was treated with topical interferon alpha with subsequent complete resolution of disease ([@B50]).

IUIS: Predominantly Antibody Deficiencies
-----------------------------------------

In this literature review, we identified 27 studies, which reported B cell lymphomas in 208 patients with predominantly antibody deficiencies. The median age at presentation was 46 years (range: 2--76 years) with a gender distribution of 34% (*n* = 71) female, 13% (*n* = 27) male, and 53% (*n* = 110) NS.

### Common Variable Immune Deficiency (CVID)

Twenty-two studies of 192 CVID patients with B-cell lymphoma are presented in [Table 1](#T1){ref-type="table"} ([@B3], [@B54]--[@B74]). Common lymphomas included unclassified NHL (32%, *n* = 62), MALT lymphoma (EMZL) (7%, *n* = 14), DLBCL (5%, *n* = 9), and HL (4%, *n* = 8). Of these, 31% (*n* = 60) cases appeared to be associated with EBV infection. Possible mechanisms of lymphomagenesis in these different cohorts included chronic antigenic stimulation and defective immune surveillance. The treatments of choice in these patients included surgical resection and/or radiotherapy with chemotherapy. Common Variable Immunodeficiency (CVID) is the most common adult humoral immunodeficiency, both in US and European studies. There are several reports documenting an increased risk of lymphoma in these patients. In a large cohort of 176 patients with CVID, an increased incidence of lymphoma (obs = 4; SIR = 12.1; 95% CI = 3.3--31.0) was noted ([@B54]). In an ESID (European Society for Immunodeficiencies) registry study of 2,212 CVID patients, a subset (*n* = 902) analysis identified 3% of patients with lymphoma ([@B106]). However, in another study from a single center, which followed 473 CVID patients over four decades, the incidence of lymphoma was higher at 8.2% ([@B74]).

### Selective IgA Deficiency

Three studies reported three cases of selective IgA deficiency with B cell lymphoma; an adult patient with apparent selective IgA deficiency who presented with a primary cutaneous MZL, a 38-year-old male with unclassified NHL and a 2-year-old boy with Burkitt-like lymphoma ([@B41], [@B54], [@B75]). It is relevant to note that a combined Danish and Swedish study of 386 patients with IgA deficiency did not show an increased risk for cancer (standardized incidence ratio = 1.0) ([@B54]).

### Activated Phosphoinositide 3-Kinase D Syndrome (APDS)

Nine patients with gain of function (GOF) mutation in PIK3CD gene (APDS) developed B cell lymphoma in the three studies identified in this review ([@B51]--[@B53]). DLBCL was the most common type (33%, *n* = 3). An EBV association was not seen in these particular cases.

### Other Ig Deficiencies

Seidemann et al. reported four cases of B cell lymphoma in different Ig subclass deficiencies (excluding selective IgA deficiency) ([@B41]). Seventy-Five Percent (*n* = 3) had Burkitt lymphoma (BL). Two died during treatment with chemotherapy, two were alive and in complete remission at last follow up.

IUS: Diseases of Immune Dysregulation
-------------------------------------

In this category, 42 cases from 20 studies were identified, and of these, 76% (*n* = 32) had an association with EBV ([@B41], [@B76]--[@B94]). The median age of the reported cases was 5 years (range: 1--33 years), 62% (*n* = 26) were male, 31% (*n* = 13) female and 7% (*n* = 3) were NS. HL (48%, *n* = 20) was the most common subtype in these disorders of immune dysregulation, followed by DLBCL (29%, *n* = 12), BL (12%, *n* = 5), unspecified NHL (7%, *n* = 3) and composite lymphoma---FL, DLBCL, HL (2%). Specific examples are discussed further.

### X-linked Lymphoproliferative Syndrome Type 1 (XLP-1)

In patients with X-linked lymphoproliferative syndrome type 1 due to genetic defects in *SH2D1A*, there were 3 studies with six patients who developed B cell lymphoma \[4 BL, 2 DLBCL ([@B77]--[@B79])\]. The median age at diagnosis of lymphoma was 5 years (range: 1--14 years), and of these cases, 50% (*n* = 3) were EBV-associated and 50% (*n* = 3) had no apparent EBV association. Since XLP1 is associated with a defective immune response to EBV related to impaired cellular cytotoxicity it is not unexpected that there would be impaired immune surveillance in these patients ([@B109]). The two patients who had a DLBCL not related to EBV presented with a testicular mass and right chest mass, respectively. In the cases with the BL, clinical presentation involved lymphadenopathy and palpable abdominal mass/obstruction or cerebellar tumor. With the exception of a single case, all patients died within 5 years of diagnosis regardless of treatment modality used.

### Interleukin-2-Inducible T-Cell Kinase (ITK) deficiency

Patients with ITK deficiency have an intrinsic susceptibility to EBV. In six studies, 13 patients with ITK deficiency ([Table 1](#T1){ref-type="table"}) who developed B cell lymphoma were identified, and all were associated with EBV ([@B80]--[@B85]). The most common was HL (84%, *n* = 11) followed by NHL (7%, *n* = 1) and DLBCL (7%, *n* = 1). The median age at presentation was 5 years (range: 1--6) with 54% (*n* = 7) female and 46% (*n* = 6) male, presenting clinically with lymphadenopathy and hepatomegaly. The treatment of choice was chemotherapy and HCT.

### Autoimmune Lymphoproliferative Syndrome (ALPS)

While there are several genetic defects associated with ALPS or ALPS-like disease, the most frequent genetic defect associated with a classic ALPS-like phenotype is heterozygous germline pathogenic variants in the *FAS* gene. In [Table 1](#T1){ref-type="table"}, there was a single report an EBV-associated composite lymphoma (FL, DLBCL, HL) in an adult male with ALPS, which was treated with R-CHOP resulting in CR ([@B76]).

### IL10-R Deficiency

Monogenic inflammatory bowel disease (IBD) can be associated with complex presentations, and patients with genetic defects in the IL-10 receptor (*IL10RA* and *IL10RB*) have particularly severe disease with additional complications. A single case report ([@B110]) and a case series has reported DLBCL in 5 patients with IL10R deficiency ([@B94]). There was no EBV association noted in any of these cases, and the median age of developing lymphoma was 5 years (range: 5--6 years). Interestingly, all patients in these series were male. Chemotherapy with COP (cyclophosphamide, vincristine, prednisone), COPADM (cyclophosphamide, vincristine, prednisone, doxorubicin, methotrexate), CYM (cytarabine, methotrexate), and ICE (ifosfamide, carboplatin, etoposide) was used with variable success. Among the five patients, two died due to disease progression during treatment, while three who received HCT remained alive and in remission on follow-up. It is evident that in this context, HCT is not only curative but may very well prevent the occurrence or recurrence of lymphoma ([@B111]).

### CD70 Deficiency

B cell lymphoma was reported in four male patients under the age of 20 with CD70 deficiency across two studies ([@B86], [@B87]). All patients presented with HL, associated with EBV infection and were managed with chemotherapy and radiotherapy. Two patients underwent HCT and complete remission was achieved in all cases.

### CD27 Deficiency

We identified one study reporting five cases (mostly females) with CD27 deficiency who developed B cell lymphoma ([@B88]). Three patients were diagnosed with HL, and two with DLBCL. All were related to EBV infection. Only two patients with HL treated with the EuroNet-PHL-C1 (EuroNet-Pediatric Hodgkin\'s Lymphoma Group-C1) protocol and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) plus radiotherapy respectively were alive and in complete remission.

### XMEN (MAGT1) Deficiency

Four studies with four patients were reported to develop B cell lymphoma in the context of MAGT1 deficiency ([@B89]--[@B92]). All were males with EBV-associated lymphomas. The ages ranged from 7 to 57 years, and the distribution of B cell lymphomas included 2 HL, 1 BL, and 1 DLBCL.

### CTP Synthase 1 (CTPS1) deficiency

One study reported two cases with EBV- associated unspecified NHL in patients with CTPS1 deficiency ([@B93]).

IUIS: Defects in Intrinsic and Innate Immunity
----------------------------------------------

### WHIM (Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis) Syndrome

WHIM syndrome is caused by gain-of-function defects in the *CXCR4* gene frequently associated with severe neutropenia and variable degree of immunodeficiency. There are two reports ([Table 1](#T1){ref-type="table"}) of B cell lymphoma (type not specified) in two adult patients with WHIM syndrome ([@B95], [@B96]). Both were associated with EBV infection leading to lymphoproliferation and ultimately lymphoma. Treatment in both cases was with CHOP chemotherapy, and one patient had a CR, while the other patient who presented with intestinal lymphoma had no response and died of intestinal perforation.

T Cell Lymphomas in PIDs {#s4}
========================

The incidence of T cell lymphomas is infrequent in PIDDs ([Table 2](#T2){ref-type="table"}). In this particular literature review, 74 patients were identified through 20 different reports. The types of T cell lymphoma identified included T cell non-Hodgkin lymphoma (TNHL) 36%, T cell lymphoblastic lymphoma (T-LL) 32%, peripheral T cell lymphomas (PTCL) 9%, granulomatous cutaneous T-cell lymphoma (G-CTCL) 4%, anaplastic large cell lymphoma (ALCL) 4%, and T cell-diffuse lymphocytic lymphoma (T-DLL) 1%. Of these cases, 41% (*n* = 30) were male, 10% (*n* = 10) were females and 46% (*n* = 34) did not report gender. The median age at the diagnosis of lymphoma was 13 years (range 0.5--68 years). It is interesting and relevant to note that the cases of T cell lymphomas were mostly observed in patients with predominantly antibody deficiencies or combined immunodeficiencies with associated or syndromic features. Only a single report is available of a patient with a combined immunodeficiency (CID) ([Table 2](#T2){ref-type="table"}), who developed T-LL and was treated with full dose NHL-BFM95 (Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster 95) on a phase1 clinical trial ([@B4]), and was in CR but subsequently died of sepsis.

###### 

Summary of T cell lymphomas in PIDDs.

  **PID**                                                                 **References**      **Proposed mechanism**                               ***N***   **Cancer**   **Age/sex**   **Manifestation/course**                                                                                                                                       **Treatment**                                                                                                                 **Outcome**
  ----------------------------------------------------------------------- ------------------- ---------------------------------------------------- --------- ------------ ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  **PREDOMINANTLY ANTIBODY DEFICIENCIES**                                                                                                                                                                                                                                                                                                                                                                                                                                            
  CVID                                                                    ([@B97])            Immune dysregulation                                 1         DLL          52/M          RUQ tenderness, early satiety. HS. erythematous skin papules.                                                                                                  Chlorambucil and Prednisone                                                                                                   Poor response, died in 2 years.
  CVID                                                                    ([@B98])            Immune dysregulation                                 1         PTCL         57/M          Fever, night sweats, progressive refractory anemia, tender inguinal lymphadenopathy                                                                            ProMACE CytaBOM                                                                                                               CR after 6 cycles
  CVID                                                                    ([@B99])            NS                                                   1         PTCL         32/F          Persistent cytopenia, progressive neurologic disease presenting as a polyradiculopathy with aseptic lymphocytic meningitis                                     cranial radiation, systemic and intra-thecal chemotherapy                                                                     Symptoms progressed. Died in few months.
  IgA deficiency                                                          ([@B100])           Immune dysregulation                                 1         PTCL         24/M          4 years after PID diagnosis: liver failure, abdominal lymphadenopathy, pancytopenia, and recurrent bacterial infections and increasing pulmonary infiltrates   None. Diagnosis on autopsy.                                                                                                   Died of pulmonary failure before diagnosis
  XLA                                                                     ([@B101])           Chronic antigenic stimulation Immune dysregulation   1         PTCL         21/M          Sustained fever, unresponsive to antibiotics                                                                                                                   NR                                                                                                                            NR
  XLA                                                                     ([@B102])           Immune dysregulation                                 1         GCTCL        33/M          Generalized asymptomatic papulonodular eruption No lymphadenopathy/organomegaly                                                                                NR                                                                                                                            NR
  IgA deficiency                                                          ([@B102])           Immune dysregulation                                 1         GCTCL        68/M          Progressive generalized papules, plaques, and tumors. Occult IgA def diagnosed after presentation.                                                             cyclophosphamide, methotrexate, etoposide, and dexamethasone                                                                  CR followed by recurrence and eventual death in 5 years
  CVID                                                                    ([@B102])           Immune dysregulation                                 1         GCTCL        44/M          progressive, asymptomatic red papules and nodules on his trunk and extremities.                                                                                Bexarotene Gemcitabine                                                                                                        Relapse and disease progression
  IgA deficiency                                                          ([@B41])            NS                                                   2         Pt1: ALCL    11/M                                                                                                                                                                         NHL-BFM                                                                                                                       CR, LFU +3.5 years
                                                                                                                                                             Pt2: TNHL    2/M                                                                                                                                                                          Non-B therapy, induction only                                                                                                 Sepsis during chemotherapy, death after 3 weeks of therapy
  CVID                                                                    ([@B71])            NS                                                   4/247     4 T-cell     NR            NR                                                                                                                                                             NR                                                                                                                            2 died, 2 responded to RT
  CVID                                                                    ([@B3])                                                                  1/416     1 PTCL       NR            NR                                                                                                                                                             NR                                                                                                                            NR
  APDS                                                                    ([@B52])            NS                                                   1/53      ALCL         NR            NR                                                                                                                                                             NR                                                                                                                            NR
  Hypogammaglobinemia                                                     ([@B41])            NS                                                   1         ALCL         15/M                                                                                                                                                                         NHL-BFM                                                                                                                       CR, LFU +2.75 years
  **COMBINED IMMUNODEFICIENCIES WITH ASSOCIATED OR SYNDROMIC FEATURES**                                                                                                                                                                                                                                                                                                                                                                                                              
  NBS                                                                     ([@B44])            Chronic antigenic stimulation                        5/57      TNHL         NR            NR                                                                                                                                                             NR                                                                                                                            15 out of 22 patients (B and T lymphomas) died, most at the beginning of the study, but 7 were clinically stable after early diagnosis and successful treatment
                                                                                              Chronic antigenic stimulation                        2/57      TLBL         NR            NR                                                                                                                                                             NR                                                                                                                            
  NBS                                                                     ([@B45])            NS                                                   21/149    TNHL         NR            NR                                                                                                                                                             NR                                                                                                                            44% of all patients were in remission, 54% died due to disease progression
  NBS                                                                     ([@B103])           EBV associated                                       1         1 TLBL       10/F          Fever, generalized lymph node enlargement, hepatosplenomegaly and mediastinal mass                                                                             BFM90 protocol                                                                                                                Alive 7 years later
  NBS                                                                     ([@B37])            NS                                                   9         Pt1: TLBL    10/F          NR                                                                                                                                                             BFM90                                                                                                                         Died of disease after protocol
                                                                                                                                                             Pt2: TLBL    8/F           NR                                                                                                                                                             BFM90                                                                                                                         Died of relapse during maintenance
                                                                                                                                                             Pt3: TLBL    16/M          NR                                                                                                                                                             BFM90                                                                                                                         Died of relapse during maintenance
                                                                                                                                                             Pt4: TLBL    12/M          NR                                                                                                                                                             BMF-90 followed by chemotherapy (ICE)                                                                                         Died of organ failure caused by sepsis
                                                                                                                                                             Pt5: AILT    8/F           NR                                                                                                                                                             BMF-90 followed by individualized chemotherapy                                                                                Died of disease
                                                                                                                                                             Pt6: TLBL    7/F           NR                                                                                                                                                             EURO-LB 02 protocol                                                                                                           Alive disease-free
                                                                                                                                                             Pt7: TLBL    3/M           NR                                                                                                                                                             EURO-LB 02 protocol                                                                                                           Alive disease-free
                                                                                                                                                             Pt8: TLBL    9/M           NR                                                                                                                                                             EURO-LB 02 protocol                                                                                                           Alive with disease
                                                                                                                                                             Pt9: TLBL    19/F          NR                                                                                                                                                             EURO-LB 02 protocol                                                                                                           Died of relapse during maintenance
  NBS                                                                     ([@B38])            NS                                                   6         Pt1: TLBL    18/M          2nd malignancy: AML                                                                                                                                            EURO-LB 02 protocol                                                                                                           Death because of 2nd malignancy (AML), 3.5 years after diagnosis
                                                                                                                                                             Pt2: TLBL    16/M          NR                                                                                                                                                             EURO-LB 02 protocol                                                                                                           CR 1 year after diagnosis
                                                                                                                                                             Pt3: TLBL    4/M           2nd malignancy: TLBL 14 years after diagnosis                                                                                                                  NHL-BFM90                                                                                                                     CR after treatment in accordance to GMALL protocol for 2nd malignancy
                                                                                                                                                             Pt4: TLBL    6/F           NR                                                                                                                                                             EURO-LB 02 protocol                                                                                                           CR 2.4 years after diagnosis
                                                                                                                                                             Pt5: TLBL    8/M           NR                                                                                                                                                             ALL-BFM-MR protocol                                                                                                           CR 1.7 years after diagnosis and 1 year after SCT
                                                                                                                                                             Pt6: TLBL    16/M          NR                                                                                                                                                             NHL-BFM95                                                                                                                     Death 1 year after diagnosis
  NBS                                                                     ([@B39])            Defective antitumor immunosurveillance               2/26      Pt1: TLBL    16/M          NR                                                                                                                                                             NR                                                                                                                            Death at 18 years
                                                                                                                                                             Pt2: TNHL    24/M          NR                                                                                                                                                             NR                                                                                                                            Death at 27 years from sepsis
  NBS                                                                     ([@B40])            NS                                                   3         Pt1: TLBL    8/F           Cervical LN                                                                                                                                                    NR                                                                                                                            Died at 11 years
                                                                                                                                                             Pt2: TLBL    16/M          Cervical LN                                                                                                                                                    NR                                                                                                                            Died at 18 years
                                                                                                                                                             Pt3: TLBL    12/M          Cervical LN                                                                                                                                                    NR                                                                                                                            Died at 13 years
  Ataxia Telangiectasia                                                   ([@B38])            NS                                                   1         Pt1: TLBL    0.5/M         2nd malignancy: B-NHL after 3.5y                                                                                                                               NHL-BFM86 modified                                                                                                            Death of second malignancy
  Ataxia Telangiectasia                                                   ([@B41])            NS                                                   1         TNHL         0.5/M         2nd malignancy: low-grade B-NHL                                                                                                                                Non-B therapy, induction with 50% dosage, then reduced maintenance; omission of therapy after 7 months from severe toxicity   Reached CR initially; died of 2nd malignancy after 3.75 years
  NBS                                                                     ([@B4])             Defective DNA repair                                 3         Pt 1: TLBL   5/M           NR                                                                                                                                                             NHL-BFM95, phase I protocol, nonmyeloablative conditioning, HSCT                                                              CR 1, alive disease-free for 1.4 years
                                                                                                                                                             Pt 2: PTCL   16/M          NR                                                                                                                                                             CHOP--CHOP--ICE-- DHAP--DHAP-- DexaBEAM                                                                                       Died of disease at 5 months after the diagnosis
                                                                                                                                                             Pt 3: TLBL   14/M          NR                                                                                                                                                             NHL-BFM95, protocol I, full dosage                                                                                            Death of sepsis in PR after 7 weeks of therapy
  **IMMUNODEFICIENCIES AFFECTING CELLULAR AND HUMORAL IMMUNITY**                                                                                                                                                                                                                                                                                                                                                                                                                     
  CID                                                                     ([@B4])             Impaired Immune function                             1         TLBL         8/M           9                                                                                                                                                              NHL-BFM95, full dosage                                                                                                        Death of sepsis in CR 2 at 2 years after the diagnosis
  **DISEASES OF IMMUNE DYSREGULATION**                                                                                                                                                                                                                                                                                                                                                                                                                                               
  CD27 deficiency                                                         ([@B88], [@B104])   EBV associated                                       1         Pt1: TCL     16/M          Oral ulcers, uveitis, chronic EBV viremia, and EBV-related LPD progressing to T-cell lymphoma                                                                  Rituximab, R-CHOP, cord HSCT                                                                                                  Alive
  Hypergammaglobinemia                                                    ([@B41])            NS                                                   1         PTCL         2/F                                                                                                                                                                          Non-B therapy, induction, followed by maintenance                                                                             Still on maintenance therapy in PR for 2 years

*AILT, (angioimmunoblastic T cell lymphoma); AML, (acute myloid leukemia); CID, (combined immunodeficiency); CVID, (Common variable immune deficiency); DLL, (diffuse lymphocytic lymphoma); CR, (complete remission); F, (female); GCTCL, (granulomatous cutaneous T-cell lymphoma); HS, (hepatosplenomegaly); LN, (lymph nodes); M, (male); NR, not reported; NBS, Nijmegan breakage syndrome; NHL-BFM, Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster; NS, not specified, PR, partial remission; ProMACE, prednisone, doxorubicin, cyclophosphamide, etoposide, methotrexate, leucovorin; Pt, patient; PTCL, peripheral T cell lymphoma; R-CHOP, Rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone; RUQ, right upper quadrant; TLBL, T lymphoblastic lymphoma; XLA, X-linked agammaglobulinemia; TCL, T cell lymphoma*.

###### 

Summary of unspecified lymphoma in PIDDs.

  **PID**                                 **Reference**      ***N***   **Proposed mechanism**   **Cancer**                  **Age/sex**   **Manifestation/course**   **Treatment**                   **Outcome**
  --------------------------------------- ------------------ --------- ------------------------ --------------------------- ------------- -------------------------- ------------------------------- -----------------------
  XMEN[^\*^](#TN1){ref-type="table-fn"}   ([@B89])           1/3       EBV associated           Lymphoma                    45/M          NR                         NR                              Died at the age of 45
  ADA deficiency                          ([@B105])          1         Not specified            Lymphoma                    NR/M          NR                         HSCT                            Died
  CVID                                    ([@B54])           1         Not specified            Malignant lymphoma          30/M          NR                         NR                              NR
  CVID                                    ([@B65], [@B66])   1/117     Not specified            Undifferentiated lymphoma   63/M          Bone marrow                Plasmapheresis, CHOP, M-BACOD   Died 2 years later
  CVID                                    ([@B106])          71/2212   Not specified            Lymphoma                    NR            NR                         NR                              NR

*CHOP, (cyclophosphamide, doxorubicin, vincristine, and prednisone); CVID, common variable immune deficiency; EBV, Epstein-Barr virus; F, female; HCT, hematopoietic cell transplantation; M, male; M-BACOD, (methotrexate, doxorubicin, cyclophosphamide, vincristine, dexamethasone); NR, not reported. \*EBV positive*.

IUIS: Diseases of Immune Dysregulation
--------------------------------------

### CD27 Deficiency

A 16 year old male presented with oral ulcers, uveitis, chronic EBV viremia, and EBV-related lymphoproliferative disorder (LPD) progressing to T-cell lymphoma was treated with rituximab, R-CHOP, and subsequently a cord blood HCT, and the patient was alive at last follow-up ([@B104]).

IUIS: Immunodeficiencies Affecting Cellular and Humoral Immunity
----------------------------------------------------------------

### CID

Only a single report of a patient with a combined immunodeficiency (CID) is reported ([Table 2](#T2){ref-type="table"}) who developed T-LL and was treated with full dose NHL-BFM95 on a phase1 clinical trial, and was in CR but subsequently died of sepsis ([@B4]).

IUIS: Predominantly Antibody Deficiencies
-----------------------------------------

In patients with humoral immune defects, there were 10 studies with 17 patients reported ([Table 2](#T2){ref-type="table"}). The types of T cell lymphomas observed were PTCL (29% *n* = 5), G-CTCL (18%, *n* = 3), ALCL (18%, *n* = 3), T-DLL (5% *n* = 1), and TNHL (5%, *n* = 1). The median age at diagnosis was 32 years (range: 2--68 years) with a distribution of males (59%, *n* = 10), females (6%, *n* = 1) and NS (35%, *n* = 6).

### Common Variable Immunodeficiency (CVID)

Of the patients with humoral defects, 53% (*n* = 9) had CVID across six studies, and the main types of T cell lymphomas included were PTCL, T-DLL, G-CTCL, and 4 unspecified T-cell lymphomas ([@B3], [@B71], [@B97]--[@B99], [@B102]). The treatment modalities used include Prom ACE (prednisone, doxorubicin, cyclophosphamide, etoposide, methotrexate, leucovorin), CytaBOM (cytarabine bleomycin, vincristine, methotrexate), radiation, systemic and intra-thecal chemotherapy. A single CVID patient presented with G-CTCL, which relapsed and progressed after treatment with bexarotene and gemcitabine. Another CVID patient developed T-DLL and had a poor response to chlorambucil and prednisone and succumbed to disease within 2 years.

### Selective IgA Deficiency (sIgAD)

As with B cell lymphoma, there were three reports of four patients with sIgAD who developed T cell lymphoma (G-CTCL, PTCL, ALCL, TNHL) ([@B41], [@B100], [@B102]). All were males, and the diagnosis was made by autopsy in one patient, while the diagnosis of occult IgA deficiency was made in the second patient after the development of malignant disease. Though this patient was treated with chemotherapy with apparent CR, there was subsequent relapse of disease and mortality within 5 years. In patients classified as having sIgAD and malignant disease, it remains an open question as to whether there was a more severe underlying immunological defect that was not identified at the time.

### Hypogammaglobinemia

Seidemann et al. reported a case of 15-year-old male with hypogammaglobulinemia who developed ALCL ([@B41]). Complete remission was achieved on treatment with chemotherapy. Last follow up was almost three years after diagnosis. A molecular etiology for the hypogammaglobulinemia was not available in this patient.

### XLA

In the 2 patients reported with XLA, the types of T cell lymphoma observed were G-CTCL and PTCL ([@B101], [@B102]).

IUIS: Combined Immunodeficiencies With Associated or Syndromic Features
-----------------------------------------------------------------------

In this category, we identified nine studies with 54 patients. Median age was 10 years (0.5--24). Similar to other categories with T cell lymphomas, males had a higher percentage (33%, *n* = 18) compared to females (15%, *n* = 8) and 52% (*n* = 28) were NS. TNHL (52%, *n* = 28) was the most common type of TCL followed by TLBL (44%, *n* = 24).

### Nijmegen Breakage Syndrome (NBS)

Similar to B cell lymphomas (BCL) in NBS, there are reports of T cell lymphoma (TCL) in this group of patients. In [Table 2](#T2){ref-type="table"}, there are eight studies with 52 patients, all under the age of 20 ([@B4], [@B37]--[@B40], [@B44], [@B45], [@B103]). The underlying mechanism for development of malignant disease is the same as for BCL and related to defects in DNA repair. The commonly used chemotherapy protocols in these patients included NHL-BFM-90, NHL-BFM-95, and EURO-LB 02.

### AT

We identified two studies reporting two cases of TCL in AT patients ([@B38], [@B41]). A 6-month-old boy was diagnosed with TLBL and treated with a modified NHL-BFM 86 regimen. He developed B-NHL at the age of four leading to death. The second patient was also a 6-month-old boy who developed T-NHL and achieved complete remission initially, but like the first patient died at the age of four due to a second malignancy (B-NHL).

Discussion {#s5}
==========

In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment.

Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs {#s6}
=======================================================================

The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers ([Figure 3](#F3){ref-type="fig"}). An underlying intrinsic susceptibility to DNA damage in some of these PIDDs, may provide a substrate for uncontrolled cell growth, impaired apoptosis of damaged cells, premature cellular senescence, all of which may be compounded by increased antigenic stimulation of adaptive lymphocytes by viruses, such as EBV ([@B112]). This uncontrolled stimulation in the setting of altered immune checkpoints and immune dysregulation characterized by T cell exhaustion, defective anti-tumor immune surveillance and overproduction of inflammatory cytokines provides a fertile setting for neoplastic transformation and lymphoproliferation ([Figure 3](#F3){ref-type="fig"}).

![Illustration of potential interplay of mechanisms implicated in pathogenesis of malignancies in PIDs.](fimmu-10-00777-g0003){#F3}

Defective DNA Repair
--------------------

DNA integrity is constantly challenged at various levels as part of physiological processes. In lymphocytes, there is particular susceptibility specifically related to intrinsic mechanisms that are part of the immune diversity generation apparatus, such as V(D)J recombination, class switch recombination (CSR), and somatic hypermutation (SMH) ([@B113]). These intrinsic "stress points" coupled with other factors, including exposure to internal mutagens (e.g., endogenous metabolites) and external factors such as ultraviolet rays, ionizing radiation and chemicals ([@B107]) sets the stage for development of dysregulated cellular proliferation in B or T cells. Therefore, it is not surprising that normally there is a highly conserved DNA repair system orchestrated by a network of enzymes, which constantly assesses and detects DNA damaging lesions, modifies or removes damaged DNA, and reconstitutes the integrity of DNA through nucleotide resynthesis and ligation ([@B114]). When these checks and balances fail in the context of monogenic defects, it promotes the development of lymphoid tumors ([@B113]). Patients with premature cellular senescence related to shortened telomeres not only have an intrinsic susceptibility to DNA damage-inducing stimuli but also may have impaired apoptosis of damaged cells, which in turn may promote lymphoproliferation.

Role of Viral Infections and Defective Immune Surveillance, and Immune Dysregulation
------------------------------------------------------------------------------------

Several of the documented PIDDs increase susceptibility to viral infections such as EBV, human papilloma virus (HPV), human herpes virus-6 (HHV-6), HHV-8, human T-cell lymphotropic virus (HTLV), Kaposi sarcoma--associated virus (KSV), and other viruses due to defective immune surveillance and immune dysregulation ([@B115]). Among these viruses, EBV represents the biggest threat because of its high prevalence (95%) and ability to transform epithelial cells, B cells, T cells and NK cells ([@B116]).

In the majority of cases, EBV virions entering through the oro-pharynx infect epithelial cells and B cells via the CD21 receptor. From a host immune system standpoint, NK cells and antigen-specific CD8+ T-cells are the main defense against primary EBV infection. Therefore, if EBV-infected B cells escape the cellular immune response, it can provoke an inflammatory outburst, resulting in cellular hyperproliferation and abnormal cell survival eventually leading to EBV-associated lymphoproliferative disorders (EBV-LPDs). EBV-LPDs consist of virus-associated hemophagocytic syndrome, non-malignant and malignant B-cell LPDs including non-Hodgkin and Hodgkin\'s types of B lymphomas and rarely EBV-positive T/NK cell lymphoma ([@B117]). The critical role of NK and T cells is demonstrated by the fact that combined B and T cell deficiency PIDDs account for approximately 2/3rd of EBV-associated LPDs in PIDDs, whereas defects in innate immunity do not significantly increase the risk of EBV-associated LPDs ([@B116]). Thus, underlying genetic defects in *SH2D1A* (SAP--XLP-1), *ITK, MAGT1, CD27, CD70, CTPS1, RASGRP1, CORO1A* and others account for the majority of EBV-LPDs.

The lack of adequate immune surveillance in the context of immune dysregulation is not uncommon in PIDDs, and though these cannot be exhaustively discussed here, failure of both innate (NK cells) and adaptive (T cells) immune cellular mechanisms facilitate viral escape and subsequent viral transformation of lymphocytes with poor cytotoxic clearance of virally-infected cells ([@B89], [@B117]). On the other hand, in certain other PIDDs, for example, the IL-10 receptor defects, there is production of pro-inflammatory cytokines due to the lack of IL-10-based regulation, and NFκB activation, with defective intra-tumoral CD8+ T cell immune surveillance and impaired cytotoxicity. This results in B cell proliferation and accumulation of somatic mutations ([@B94], [@B111]). Therefore, this is associated with a non-EBV-associated lymphoproliferation.

Chronic Antigenic Stimulation
-----------------------------

Patients with PIDDs are more likely to develop persistence of antigens, and therefore ongoing stimulation of effector immune cells. T and B cells respond to external stimuli (antigens) and subsequently eliminate non-self-antigens (pathogen-infected and/or transformed cells). Sustained antigenic stimulation, in the context of cellular and systemic immune compromise, is likely to increase T cell exhaustion with progressive loss of cytokine secretion (IL-2, TNF-\<), impairment of IFN-γ production, and in extreme cases premature apoptosis of CD8+ T cells ([@B118]). This quantitative and qualitative loss of the CD8+ T cell immune response against tumor cells eventually results in the development of lymphomas, and another plausible mechanism for tumor development in PIDDs.

Altered Immune Checkpoints
--------------------------

One of the primary mechanisms by which tumors escape the immune system is by engaging immune checkpoints ([@B119]), which is why immune checkpoint inhibitors (ICIs) were approved for the treatment of cancers and are now used in 14 different types of cancer ([@B120]). This issue is relevant to the lymphomas, which develop in PIDDs as it has been shown that PDL-1 protein is overexpressed in most EBV-associated tumors ([@B121]). Further, copy number variations (CNVs) at 9p24.1 have also been reported, and this is a locus, which harbors PD-1 ([@B122]). However, only one of two studies found amplifications of chromosome 9p via array CGH (comparative genomic hybridization) in EBV+ DLBCL ([@B123]). These findings raise the possibility that EBV+ DLBCL evades immune surveillance by selectively targeting the PD1/PDL pathway. Therefore, there may be some value to using immune checkpoint inhibitors in PIDDs for the treatment of lymphoma, and this raises the need for clinical trials in this area.

Treatment of B and T Cell Lymphomas in PIDDs {#s7}
============================================

Clinical Presentation, Diagnosis and Staging
--------------------------------------------

PIDD patients often present with advanced disease, and extranodal sites of disease, including bone marrow, liver, and spleen, and the presence of B-symptoms is quite common. There is no difference in how the diagnosis of lymphoma is established, whether in in PIDDs or non-intrinsic lymphoid malignancies, and it usually involves tissue biopsy, most frequently of lymph nodes.

Clinical evaluation should include standard workflow of history and physical, complete blood count with differential, liver and kidney function and baseline pulmonary function test for adult patients, if they will undergo bleomycin-containing regimens in the context of HL. Additional work-up to assess the degree of immune impairment, based on underlying genetic defect is essential for this patient population, and should include evaluation of radiosensitivity (especially if the genetic defect is known to predispose to this) so that appropriate treatment regimens can be formulated. Principles of diagnostic imaging may be extrapolated from imaging recommendations for Hodgkin\'s lymphoma in HIV patients, which suggests 18FDG-PET with integrated or concurrent CT (computerized tomography) of the neck, chest, abdomen, and pelvis. Since 18FDG-PET imaging has not been validated in this setting, it is unclear whether a bone marrow biopsy can be omitted. The interpretation of 18FDG-PET scan be challenging in presence of concurrent infections, which is not uncommon in these patients ([@B124]).

Treatment Options
-----------------

While there are no specific treatment options for lymphoma in PIDD patients, radiation-based therapies should be avoided in patients with known genetic defects that predispose to radiosensitivity. Most frequently standard treatment options are based on type of lymphoma, such as B or T cell, indolent, aggressive or very aggressive and patient-related characteristics such as age, comorbidities, immune status, and degree of immune compromise. While there are no large or randomized studies to confirm this, small series and case reports show that response to the treatment and prognosis is inferior in PIDD patients when compared to non-PIDD patients, largely related to their inability to tolerate standard chemotherapy, and susceptibility to life-threatening infections ([@B25]). HCT remains the only viable curative option for many of these diseases, though its efficacy of HCT is variable across different PIDDs. For example, the role of HCT in severe combined immune deficiencies (SCID) is well established and it has been consistently replicated ([@B125]). HCT is not a standard treatment of choice in CVID, especially those without a molecular defect, though it may be warranted in certain cases depending on the presentation and associated co-morbidities. In circumstances, of a specific molecular diagnosis replacing or clarifying the underling CVID, HCT may be the most optimal long-term treatment of choice, even though more targeted therapies may be available. HCT for CVID was reported in a multicenter experience for 25 patients transplanted at 14 centers in Europe, the US, and Japan, and though it may be considered for lymphoma in this context, the risk of transplant-related mortality (TRM) should be clearly weighed against the potential benefits ([@B126]). Several retrospective studies have reported outcomes of HCT as across a range of PIDDs, including SCID ([@B127]), and Wiskott Aldrich Syndrome ([@B128]). Only case reports or small case series are available for successful treatment in patients with other PIDDs such as GATA2 haploinsufficiency, IL-10 receptor or XIAP deficiencies. Despite the limited experience, data strongly favors the early use of HCT in the setting of IL-10 receptor deficiency ([@B111]). Recently, a retrospective case series of 29 adult patients with a variety of PIDDs (mean age: 24 years, range: 17--50 years) treated with reduced intensity conditioning (RIC)-HCT was published. This study reported an overall survival of 85.2% at 3 years ([@B129]). These data provide support for moving forward with HCT in adult PIDD patients. As such, in addition to the treatment of lymphomas, HCT can be lifesaving in patients with PIDDs who develop very severe complications, including susceptibility to life-threatening infections, bone marrow failure, autoimmune and autoinflammatory diseases, other malignancies, and hemophagocytic syndrome. Despite all these potential benefits, it remains to be ascertained as to whether early HCT can reduce the risk of developing lymphoma in these PIDD patients in the long term.

There is no consistent evidence to support the use of newer immunotherapies for treatment of lymphoma in PIDDs but these therapies hold significant mechanistic promise for personalized, chemotherapy-free treatments. Potential immunotherapy options include monoclonal antibody-based immunotherapy (e.g., Rituximab, Obinutuzumab, Epratuzumab), conjugated antibodies (Brentuximab Vedotin), Bi-Specific T cell engaging (BiTE) antibodies (Blinatumumab), Anti-PD1(Pembrolizumab, Nivolumab), Anti PDL-1 (Atezolizumab and Darvalumab), and anti-CTLA4 checkpoint inhibitors (e.g., Ipilimumab). The role of adoptive T cell therapies such as chimeric antigen receptor (CAR) T-cells remains uncertain at this point ([@B130]). While these targeted therapies may have value, they may also pose an increased risk as a result of immune manipulation in the context of an underlying immune deficiency or immune dysregulation.

While there are no reports for successful use of immune checkpoint inhibitors or BiTE antibodies, complete remission with Rituximab and Brentuximab Vedotin was reported in an adult female patient with CVID -associated classic HL, while two other cases of pediatric CVID-associated HL succumbed to severe infection related to chemotherapy ([@B61]).

Conclusions {#s8}
===========

Though this is not a comprehensive summary of malignancies in PIDDs, or even lymphoproliferative disease in this area, this review summarizes the Medline-indexed published reports of B and T lymphomas in patients with PIDDs. This report highlights the diversity of malignant lymphoproliferative disorders in setting of PIDDs, and its associated challenges of diagnosis and treatment. The pathological classification and nomenclature for the lymphoid malignancies with variably reported and postulated underlying mechanisms were inconsistent and inadequate for many of these published reports. A wide range of treatment options were utilized, and response rate was highly variable suggesting an empirical approach rather than a systematic and tailored treatment regimen, based on underlying genetic defect, and degree of immunological impairment. HCT and gene therapy (where available) remains the best treatment option for many, but not all of these patients, and should be promptly initiated after diagnosis, particularly in some conditions, such as SCID, WAS, IL10 receptor deficiency among others. HCT, as a therapeutic option, remains significantly under-utilized in adult patients, likely related to inadequate awareness among adult hematologists, and these patients may benefit from increased utilization of HCT in appropriate settings. We highlight the significant need of unifying nomenclature, pathological analysis, and assessment of mechanisms of lymphomagenesis in these patients to develop better and more personalized treatment regimens. Also, there is a considerable urgency to conduct clinical trials to develop evidence-based treatment plans that considers the underlying immunodeficiency rather than using approaches extrapolated from non-PIDD settings ([@B131]). It is recognized that there has been a recent effort to standardize classification and nomenclature in immunodeficiency-associated malignant LPDs, but this is largely focused on secondary immunodeficiency disorders, in contrast to primary, though presumably some of the same standards could be applied ([@B132]), but this should be undertaken specifically for PIDDs, to fully understand the similarities and differences in pathology.
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